id	sid	tid	token	lemma	pos
dti-1415	1	1	https://doi.org/10.1177/1177392819861987	https://doi.org/10.1177/1177392819861987	PROPN
dti-1415	1	2	drug	drug	NOUN
dti-1415	1	3	target	target	NOUN
dti-1415	1	4	insights	insight	NOUN
dti-1415	1	5	volume	volume	VERB
dti-1415	1	6	13	13	NUM
dti-1415	1	7	:	:	PUNCT
dti-1415	1	8	1–2	1–2	NUM
dti-1415	1	9	©	©	ADP
dti-1415	1	10	the	the	DET
dti-1415	1	11	author(s	author(s	NOUN
dti-1415	1	12	)	)	PUNCT
dti-1415	1	13	2019	2019	NUM
dti-1415	1	14	article	article	NOUN
dti-1415	1	15	reuse	reuse	VERB
dti-1415	1	16	guidelines	guideline	NOUN
dti-1415	1	17	:	:	PUNCT
dti-1415	1	18	sagepub.com/journals-permissions	sagepub.com/journals-permission	NOUN
dti-1415	1	19	doi	doi	NOUN
dti-1415	1	20	:	:	PUNCT
dti-1415	1	21	10.1177/1177392819861987	10.1177/1177392819861987	NUM
dti-1415	1	22	creative	creative	ADJ
dti-1415	1	23	commons	commons	PROPN
dti-1415	1	24	non	non	ADJ
dti-1415	1	25	commercial	commercial	PROPN
dti-1415	1	26	cc	cc	PROPN
dti-1415	1	27	by	by	ADP
dti-1415	1	28	-	-	PUNCT
dti-1415	1	29	nc	nc	PROPN
dti-1415	1	30	:	:	PUNCT
dti-1415	1	31	this	this	DET
dti-1415	1	32	article	article	NOUN
dti-1415	1	33	is	be	AUX
dti-1415	1	34	distributed	distribute	VERB
dti-1415	1	35	under	under	ADP
dti-1415	1	36	the	the	DET
dti-1415	1	37	terms	term	NOUN
dti-1415	1	38	of	of	ADP
dti-1415	1	39	the	the	DET
dti-1415	1	40	creative	creative	ADJ
dti-1415	1	41	commons	common	NOUN
dti-1415	1	42	attribution	attribution	NOUN
dti-1415	1	43	-	-	PUNCT
dti-1415	1	44	noncommercial	noncommercial	ADJ
dti-1415	1	45	4.0	4.0	NUM
dti-1415	1	46	license	license	NOUN
dti-1415	1	47	(	(	PUNCT
dti-1415	1	48	http://www.creativecommons.org/licenses/by-nc/4.0/	http://www.creativecommons.org/licenses/by-nc/4.0/	PROPN
dti-1415	1	49	)	)	PUNCT
dti-1415	1	50	which	which	PRON
dti-1415	1	51	permits	permit	VERB
dti-1415	1	52	non	non	ADJ
dti-1415	1	53	-	-	ADJ
dti-1415	1	54	commercial	commercial	ADJ
dti-1415	1	55	use	use	NOUN
dti-1415	1	56	,	,	PUNCT
dti-1415	1	57	reproduction	reproduction	NOUN
dti-1415	1	58	and	and	CCONJ
dti-1415	1	59	distribution	distribution	NOUN
dti-1415	1	60	of	of	ADP
dti-1415	1	61	the	the	DET
dti-1415	1	62	work	work	NOUN
dti-1415	1	63	without	without	ADP
dti-1415	1	64	further	further	ADJ
dti-1415	1	65	permission	permission	NOUN
dti-1415	1	66	provided	provide	VERB
dti-1415	1	67	the	the	DET
dti-1415	1	68	original	original	ADJ
dti-1415	1	69	work	work	NOUN
dti-1415	1	70	is	be	AUX
dti-1415	1	71	attributed	attribute	VERB
dti-1415	1	72	as	as	ADP
dti-1415	1	73	specified	specify	VERB
dti-1415	1	74	on	on	ADP
dti-1415	1	75	the	the	DET
dti-1415	1	76	sage	sage	NOUN
dti-1415	1	77	and	and	CCONJ
dti-1415	1	78	open	open	ADJ
dti-1415	1	79	access	access	NOUN
dti-1415	1	80	pages	page	NOUN
dti-1415	1	81	(	(	PUNCT
dti-1415	1	82	https://us.sagepub.com/en-us/nam/open-access-at-sage	https://us.sagepub.com/en-us/nam/open-access-at-sage	NOUN
dti-1415	1	83	)	)	PUNCT
dti-1415	1	84	.	.	PUNCT
dti-1415	2	1	venous	venous	ADJ
dti-1415	2	2	thromboembolism	thromboembolism	NOUN
dti-1415	2	3	(	(	PUNCT
dti-1415	2	4	vte	vte	NOUN
dti-1415	2	5	)	)	PUNCT
dti-1415	2	6	,	,	PUNCT
dti-1415	2	7	that	that	PRON
dti-1415	2	8	includes	include	VERB
dti-1415	2	9	deep	deep	ADJ
dti-1415	2	10	vein	vein	ADJ
dti-1415	2	11	thrombosis	thrombosis	NOUN
dti-1415	2	12	(	(	PUNCT
dti-1415	2	13	dvt	dvt	PROPN
dti-1415	2	14	)	)	PUNCT
dti-1415	2	15	and	and	CCONJ
dti-1415	2	16	pulmonary	pulmonary	ADJ
dti-1415	2	17	embolism	embolism	NOUN
dti-1415	2	18	(	(	PUNCT
dti-1415	2	19	pe	pe	INTJ
dti-1415	2	20	)	)	PUNCT
dti-1415	2	21	,	,	PUNCT
dti-1415	2	22	is	be	AUX
dti-1415	2	23	a	a	DET
dti-1415	2	24	common	common	ADJ
dti-1415	2	25	and	and	CCONJ
dti-1415	2	26	potentially	potentially	ADV
dti-1415	2	27	fatal	fatal	ADJ
dti-1415	2	28	disease	disease	NOUN
dti-1415	2	29	.	.	PUNCT
dti-1415	3	1	the	the	DET
dti-1415	3	2	cause	cause	NOUN
dti-1415	3	3	of	of	ADP
dti-1415	3	4	vte	vte	NOUN
dti-1415	3	5	includes	include	VERB
dti-1415	3	6	cancer	cancer	NOUN
dti-1415	3	7	,	,	PUNCT
dti-1415	3	8	systemic	systemic	ADJ
dti-1415	3	9	,	,	PUNCT
dti-1415	3	10	surgical	surgical	ADJ
dti-1415	3	11	,	,	PUNCT
dti-1415	3	12	and	and	CCONJ
dti-1415	3	13	medication	medication	NOUN
dti-1415	3	14	-	-	PUNCT
dti-1415	3	15	related	relate	VERB
dti-1415	3	16	conditions	condition	NOUN
dti-1415	3	17	and	and	CCONJ
dti-1415	3	18	its	its	PRON
dti-1415	3	19	treatment	treatment	NOUN
dti-1415	3	20	is	be	AUX
dti-1415	3	21	based	base	VERB
dti-1415	3	22	on	on	ADP
dti-1415	3	23	anticoagulation.1	anticoagulation.1	PROPN
dti-1415	3	24	we	we	PRON
dti-1415	3	25	present	present	VERB
dti-1415	3	26	the	the	DET
dti-1415	3	27	case	case	NOUN
dti-1415	3	28	of	of	ADP
dti-1415	3	29	a	a	DET
dti-1415	3	30	43	43	NUM
dti-1415	3	31	-	-	PUNCT
dti-1415	3	32	year	year	NOUN
dti-1415	3	33	-	-	PUNCT
dti-1415	3	34	old	old	ADJ
dti-1415	3	35	man	man	NOUN
dti-1415	3	36	with	with	ADP
dti-1415	3	37	a	a	DET
dti-1415	3	38	history	history	NOUN
dti-1415	3	39	of	of	ADP
dti-1415	3	40	severe	severe	ADJ
dti-1415	3	41	extrinsic	extrinsic	ADJ
dti-1415	3	42	allergic	allergic	ADJ
dti-1415	3	43	asthma	asthma	NOUN
dti-1415	3	44	treated	treat	VERB
dti-1415	3	45	with	with	ADP
dti-1415	3	46	once	once	ADV
dti-1415	3	47	-	-	PUNCT
dti-1415	3	48	monthly	monthly	ADJ
dti-1415	3	49	omalizumab	omalizumab	NOUN
dti-1415	3	50	(	(	PUNCT
dti-1415	3	51	600	600	NUM
dti-1415	3	52	mg	mg	NOUN
dti-1415	3	53	)	)	PUNCT
dti-1415	3	54	for	for	ADP
dti-1415	3	55	the	the	DET
dti-1415	3	56	last	last	ADJ
dti-1415	3	57	15	15	NUM
dti-1415	3	58	months	month	NOUN
dti-1415	3	59	.	.	PUNCT
dti-1415	4	1	he	he	PRON
dti-1415	4	2	was	be	AUX
dti-1415	4	3	not	not	PART
dti-1415	4	4	receiving	receive	VERB
dti-1415	4	5	other	other	ADJ
dti-1415	4	6	treatments	treatment	NOUN
dti-1415	4	7	.	.	PUNCT
dti-1415	5	1	he	he	PRON
dti-1415	5	2	presented	present	VERB
dti-1415	5	3	to	to	ADP
dti-1415	5	4	the	the	DET
dti-1415	5	5	emergency	emergency	NOUN
dti-1415	5	6	room	room	NOUN
dti-1415	5	7	with	with	ADP
dti-1415	5	8	a	a	DET
dti-1415	5	9	2	2	NUM
dti-1415	5	10	-	-	PUNCT
dti-1415	5	11	week	week	NOUN
dti-1415	5	12	history	history	NOUN
dti-1415	5	13	of	of	ADP
dti-1415	5	14	right	right	ADV
dti-1415	5	15	lower	low	ADJ
dti-1415	5	16	limb	limb	NOUN
dti-1415	5	17	pain	pain	NOUN
dti-1415	5	18	and	and	CCONJ
dti-1415	5	19	chest	chest	NOUN
dti-1415	5	20	pleuritic	pleuritic	ADJ
dti-1415	5	21	pain	pain	NOUN
dti-1415	5	22	.	.	PUNCT
dti-1415	6	1	on	on	ADP
dti-1415	6	2	admission	admission	NOUN
dti-1415	6	3	,	,	PUNCT
dti-1415	6	4	blood	blood	NOUN
dti-1415	6	5	pressure	pressure	NOUN
dti-1415	6	6	was	be	AUX
dti-1415	6	7	160/94	160/94	NUM
dti-1415	6	8	mm	mm	NUM
dti-1415	6	9	hg	hg	NOUN
dti-1415	6	10	,	,	PUNCT
dti-1415	6	11	heart	heart	NOUN
dti-1415	6	12	rate	rate	NOUN
dti-1415	6	13	was	be	AUX
dti-1415	6	14	93	93	NUM
dti-1415	6	15	bpm	bpm	NOUN
dti-1415	6	16	,	,	PUNCT
dti-1415	6	17	and	and	CCONJ
dti-1415	6	18	basal	basal	VERB
dti-1415	6	19	oxygen	oxygen	NOUN
dti-1415	6	20	saturation	saturation	NOUN
dti-1415	6	21	was	be	AUX
dti-1415	6	22	98	98	NUM
dti-1415	6	23	%	%	NOUN
dti-1415	6	24	.	.	PUNCT
dti-1415	7	1	the	the	DET
dti-1415	7	2	remainder	remainder	NOUN
dti-1415	7	3	of	of	ADP
dti-1415	7	4	physical	physical	ADJ
dti-1415	7	5	examination	examination	NOUN
dti-1415	7	6	was	be	AUX
dti-1415	7	7	normal	normal	ADJ
dti-1415	7	8	and	and	CCONJ
dti-1415	7	9	no	no	DET
dti-1415	7	10	signs	sign	NOUN
dti-1415	7	11	of	of	ADP
dti-1415	7	12	dvt	dvt	PROPN
dti-1415	7	13	were	be	AUX
dti-1415	7	14	found	find	VERB
dti-1415	7	15	.	.	PUNCT
dti-1415	8	1	c	c	X
dti-1415	8	2	-	-	PUNCT
dti-1415	8	3	reactive	reactive	ADJ
dti-1415	8	4	protein	protein	NOUN
dti-1415	8	5	was	be	AUX
dti-1415	8	6	3.2	3.2	NUM
dti-1415	8	7	mg	mg	PROPN
dti-1415	8	8	/	/	SYM
dti-1415	8	9	dl	dl	PROPN
dti-1415	8	10	(	(	PUNCT
dti-1415	8	11	normal	normal	ADJ
dti-1415	8	12	<	<	X
dti-1415	8	13	0.5	0.5	NUM
dti-1415	8	14	mg	mg	PROPN
dti-1415	8	15	/	/	SYM
dti-1415	8	16	dl	dl	PROPN
dti-1415	8	17	)	)	PUNCT
dti-1415	8	18	and	and	CCONJ
dti-1415	8	19	d	d	X
dti-1415	8	20	-	-	PUNCT
dti-1415	8	21	dimer	dimer	NOUN
dti-1415	8	22	was	be	AUX
dti-1415	8	23	reported	report	VERB
dti-1415	8	24	as	as	ADP
dti-1415	8	25	5.113	5.113	NUM
dti-1415	8	26	ng/	ng/	ADJ
dti-1415	8	27	ml	ml	INTJ
dti-1415	8	28	(	(	PUNCT
dti-1415	8	29	normal	normal	ADJ
dti-1415	8	30	<	<	X
dti-1415	8	31	250	250	NUM
dti-1415	8	32	)	)	PUNCT
dti-1415	8	33	.	.	PUNCT
dti-1415	9	1	the	the	DET
dti-1415	9	2	ct	ct	PROPN
dti-1415	9	3	pulmonary	pulmonary	ADJ
dti-1415	9	4	angiography	angiography	NOUN
dti-1415	9	5	showed	show	VERB
dti-1415	9	6	bilateral	bilateral	ADJ
dti-1415	9	7	pe	pe	NOUN
dti-1415	9	8	with	with	ADP
dti-1415	9	9	right	right	ADJ
dti-1415	9	10	-	-	PUNCT
dti-1415	9	11	sided	sided	ADJ
dti-1415	9	12	pulmonary	pulmonary	ADJ
dti-1415	9	13	infarction	infarction	NOUN
dti-1415	9	14	and	and	CCONJ
dti-1415	9	15	ultrasound	ultrasound	NOUN
dti-1415	9	16	of	of	ADP
dti-1415	9	17	right	right	ADV
dti-1415	9	18	lower	low	ADJ
dti-1415	9	19	limb	limb	NOUN
dti-1415	9	20	confirmed	confirm	VERB
dti-1415	9	21	distal	distal	ADJ
dti-1415	9	22	dvt	dvt	PROPN
dti-1415	9	23	.	.	PUNCT
dti-1415	10	1	he	he	PRON
dti-1415	10	2	was	be	AUX
dti-1415	10	3	admitted	admit	VERB
dti-1415	10	4	and	and	CCONJ
dti-1415	10	5	low	low	ADJ
dti-1415	10	6	molecular	molecular	ADJ
dti-1415	10	7	weight	weight	NOUN
dti-1415	10	8	heparin	heparin	NOUN
dti-1415	10	9	was	be	AUX
dti-1415	10	10	started	start	VERB
dti-1415	10	11	.	.	PUNCT
dti-1415	11	1	pulmonary	pulmonary	ADJ
dti-1415	11	2	embolism	embolism	NOUN
dti-1415	11	3	severity	severity	NOUN
dti-1415	11	4	index	index	NOUN
dti-1415	11	5	(	(	PUNCT
dti-1415	11	6	pesi	pesi	NOUN
dti-1415	11	7	)	)	PUNCT
dti-1415	11	8	score	score	NOUN
dti-1415	11	9	was	be	AUX
dti-1415	11	10	53	53	NUM
dti-1415	11	11	points	point	NOUN
dti-1415	11	12	(	(	PUNCT
dti-1415	11	13	class	class	NOUN
dti-1415	11	14	i	i	NOUN
dti-1415	11	15	mortality	mortality	NOUN
dti-1415	11	16	risk	risk	NOUN
dti-1415	11	17	)	)	PUNCT
dti-1415	11	18	.	.	PUNCT
dti-1415	12	1	echocardiogram	echocardiogram	NOUN
dti-1415	12	2	showed	show	VERB
dti-1415	12	3	mild	mild	ADJ
dti-1415	12	4	dilation	dilation	NOUN
dti-1415	12	5	of	of	ADP
dti-1415	12	6	the	the	DET
dti-1415	12	7	right	right	ADJ
dti-1415	12	8	ventricle	ventricle	NOUN
dti-1415	12	9	,	,	PUNCT
dti-1415	12	10	the	the	DET
dti-1415	12	11	right	right	NOUN
dti-1415	12	12	-	-	PUNCT
dti-1415	12	13	to	to	ADP
dti-1415	12	14	-	-	PUNCT
dti-1415	12	15	left	leave	VERB
dti-1415	12	16	ventricle	ventricle	NOUN
dti-1415	12	17	diameter	diameter	NOUN
dti-1415	12	18	ratio	ratio	NOUN
dti-1415	12	19	was	be	AUX
dti-1415	12	20	0.85	0.85	NUM
dti-1415	12	21	(	(	PUNCT
dti-1415	12	22	normal	normal	ADJ
dti-1415	12	23	)	)	PUNCT
dti-1415	12	24	,	,	PUNCT
dti-1415	12	25	with	with	ADP
dti-1415	12	26	normal	normal	ADJ
dti-1415	12	27	systolic	systolic	ADJ
dti-1415	12	28	function	function	NOUN
dti-1415	12	29	and	and	CCONJ
dti-1415	12	30	normal	normal	ADJ
dti-1415	12	31	tricuspid	tricuspid	NOUN
dti-1415	12	32	annular	annular	ADJ
dti-1415	12	33	plane	plane	NOUN
dti-1415	12	34	systolic	systolic	ADJ
dti-1415	12	35	excursion	excursion	NOUN
dti-1415	12	36	(	(	PUNCT
dti-1415	12	37	22	22	NUM
dti-1415	12	38	mm	mm	NOUN
dti-1415	12	39	)	)	PUNCT
dti-1415	12	40	.	.	PUNCT
dti-1415	13	1	the	the	DET
dti-1415	13	2	patient	patient	NOUN
dti-1415	13	3	’s	’s	PART
dti-1415	13	4	hospital	hospital	NOUN
dti-1415	13	5	stay	stay	NOUN
dti-1415	13	6	was	be	AUX
dti-1415	13	7	uneventful	uneventful	ADJ
dti-1415	13	8	and	and	CCONJ
dti-1415	13	9	he	he	PRON
dti-1415	13	10	was	be	AUX
dti-1415	13	11	discharged	discharge	VERB
dti-1415	13	12	4	4	NUM
dti-1415	13	13	days	day	NOUN
dti-1415	13	14	later	later	ADV
dti-1415	13	15	under	under	ADP
dti-1415	13	16	treatment	treatment	NOUN
dti-1415	13	17	with	with	ADP
dti-1415	13	18	rivaroxaban	rivaroxaban	NOUN
dti-1415	13	19	.	.	PUNCT
dti-1415	14	1	treatment	treatment	NOUN
dti-1415	14	2	with	with	ADP
dti-1415	14	3	omalizumab	omalizumab	NOUN
dti-1415	14	4	was	be	AUX
dti-1415	14	5	stopped	stop	VERB
dti-1415	14	6	.	.	PUNCT
dti-1415	15	1	no	no	DET
dti-1415	15	2	known	know	VERB
dti-1415	15	3	risk	risk	NOUN
dti-1415	15	4	factors	factor	NOUN
dti-1415	15	5	were	be	AUX
dti-1415	15	6	identified	identify	VERB
dti-1415	15	7	:	:	PUNCT
dti-1415	15	8	his	his	PRON
dti-1415	15	9	body	body	NOUN
dti-1415	15	10	mass	mass	NOUN
dti-1415	15	11	index	index	NOUN
dti-1415	15	12	was	be	AUX
dti-1415	15	13	normal	normal	ADJ
dti-1415	15	14	(	(	PUNCT
dti-1415	15	15	24	24	NUM
dti-1415	15	16	kg	kg	PROPN
dti-1415	15	17	/	/	SYM
dti-1415	15	18	m2	m2	PROPN
dti-1415	15	19	)	)	PUNCT
dti-1415	15	20	and	and	CCONJ
dti-1415	15	21	he	he	PRON
dti-1415	15	22	denied	deny	VERB
dti-1415	15	23	any	any	DET
dti-1415	15	24	history	history	NOUN
dti-1415	15	25	of	of	ADP
dti-1415	15	26	smoking	smoking	NOUN
dti-1415	15	27	;	;	PUNCT
dti-1415	15	28	he	he	PRON
dti-1415	15	29	had	have	VERB
dti-1415	15	30	not	not	PART
dti-1415	15	31	recent	recent	ADJ
dti-1415	15	32	history	history	NOUN
dti-1415	15	33	of	of	ADP
dti-1415	15	34	immobilization	immobilization	NOUN
dti-1415	15	35	or	or	CCONJ
dti-1415	15	36	prolonged	prolonged	ADJ
dti-1415	15	37	travel	travel	NOUN
dti-1415	15	38	;	;	PUNCT
dti-1415	15	39	no	no	DET
dti-1415	15	40	family	family	NOUN
dti-1415	15	41	history	history	NOUN
dti-1415	15	42	of	of	ADP
dti-1415	15	43	vte	vte	NOUN
dti-1415	15	44	was	be	AUX
dti-1415	15	45	present	present	ADJ
dti-1415	15	46	.	.	PUNCT
dti-1415	16	1	a	a	DET
dti-1415	16	2	colonoscopy	colonoscopy	NOUN
dti-1415	16	3	was	be	AUX
dti-1415	16	4	normal	normal	ADJ
dti-1415	16	5	,	,	PUNCT
dti-1415	16	6	and	and	CCONJ
dti-1415	16	7	prostate	prostate	NOUN
dti-1415	16	8	-	-	PUNCT
dti-1415	16	9	specific	specific	ADJ
dti-1415	16	10	antigen	antigen	NOUN
dti-1415	16	11	was	be	AUX
dti-1415	16	12	within	within	ADP
dti-1415	16	13	normal	normal	ADJ
dti-1415	16	14	range	range	NOUN
dti-1415	16	15	(	(	PUNCT
dti-1415	16	16	0.41	0.41	NUM
dti-1415	16	17	µg	µg	NOUN
dti-1415	16	18	/	/	SYM
dti-1415	16	19	l	l	NOUN
dti-1415	16	20	)	)	PUNCT
dti-1415	16	21	.	.	PUNCT
dti-1415	17	1	thrombophilia	thrombophilia	PROPN
dti-1415	17	2	testing	testing	NOUN
dti-1415	17	3	including	include	VERB
dti-1415	17	4	antithrombin	antithrombin	NOUN
dti-1415	17	5	,	,	PUNCT
dti-1415	17	6	homocysteine	homocysteine	NOUN
dti-1415	17	7	,	,	PUNCT
dti-1415	17	8	protein	protein	NOUN
dti-1415	17	9	c	c	NOUN
dti-1415	17	10	and	and	CCONJ
dti-1415	17	11	s	s	PROPN
dti-1415	17	12	,	,	PUNCT
dti-1415	17	13	antiphospholipid	antiphospholipid	NOUN
dti-1415	17	14	antibodies	antibody	NOUN
dti-1415	17	15	,	,	PUNCT
dti-1415	17	16	factor	factor	NOUN
dti-1415	17	17	v	v	NOUN
dti-1415	17	18	leiden	leiden	PROPN
dti-1415	17	19	,	,	PUNCT
dti-1415	17	20	and	and	CCONJ
dti-1415	17	21	prothrombin	prothrombin	NOUN
dti-1415	17	22	mutation	mutation	NOUN
dti-1415	17	23	was	be	AUX
dti-1415	17	24	performed	perform	VERB
dti-1415	17	25	3	3	NUM
dti-1415	17	26	months	month	NOUN
dti-1415	17	27	after	after	ADP
dti-1415	17	28	the	the	DET
dti-1415	17	29	vte	vte	NOUN
dti-1415	17	30	event	event	NOUN
dti-1415	17	31	,	,	PUNCT
dti-1415	17	32	and	and	CCONJ
dti-1415	17	33	it	it	PRON
dti-1415	17	34	was	be	AUX
dti-1415	17	35	normal	normal	ADJ
dti-1415	17	36	.	.	PUNCT
dti-1415	18	1	anticoagulation	anticoagulation	NOUN
dti-1415	18	2	was	be	AUX
dti-1415	18	3	maintained	maintain	VERB
dti-1415	18	4	for	for	ADP
dti-1415	18	5	6	6	NUM
dti-1415	18	6	months	month	NOUN
dti-1415	18	7	.	.	PUNCT
dti-1415	19	1	c	c	X
dti-1415	19	2	-	-	PUNCT
dti-1415	19	3	reactive	reactive	ADJ
dti-1415	19	4	protein	protein	NOUN
dti-1415	19	5	was	be	AUX
dti-1415	19	6	0.3	0.3	NUM
dti-1415	19	7	mg	mg	PROPN
dti-1415	19	8	/	/	SYM
dti-1415	19	9	dl	dl	PROPN
dti-1415	19	10	and	and	CCONJ
dti-1415	19	11	d	d	X
dti-1415	19	12	-	-	PUNCT
dti-1415	19	13	dimer	dimer	NOUN
dti-1415	19	14	was	be	AUX
dti-1415	19	15	90	90	NUM
dti-1415	19	16	ng	ng	NOUN
dti-1415	19	17	/	/	SYM
dti-1415	20	1	ml	ml	NOUN
dti-1415	20	2	after	after	ADP
dti-1415	20	3	3	3	NUM
dti-1415	20	4	months	month	NOUN
dti-1415	20	5	of	of	ADP
dti-1415	20	6	the	the	DET
dti-1415	20	7	vte	vte	NOUN
dti-1415	20	8	episode	episode	NOUN
dti-1415	20	9	.	.	PUNCT
dti-1415	21	1	the	the	DET
dti-1415	21	2	naranjo	naranjo	PROPN
dti-1415	21	3	adverse	adverse	ADJ
dti-1415	21	4	drug	drug	NOUN
dti-1415	21	5	reaction	reaction	NOUN
dti-1415	21	6	(	(	PUNCT
dti-1415	21	7	adr	adr	PROPN
dti-1415	21	8	)	)	PUNCT
dti-1415	21	9	probability	probability	NOUN
dti-1415	21	10	scale	scale	NOUN
dti-1415	21	11	classifies	classify	VERB
dti-1415	21	12	this	this	PRON
dti-1415	21	13	as	as	ADP
dti-1415	21	14	a	a	DET
dti-1415	21	15	probable	probable	ADJ
dti-1415	21	16	adr	adr	NOUN
dti-1415	21	17	(	(	PUNCT
dti-1415	21	18	score	score	NOUN
dti-1415	21	19	of	of	ADP
dti-1415	21	20	6	6	NUM
dti-1415	21	21	:	:	PUNCT
dti-1415	21	22	there	there	PRON
dti-1415	21	23	are	be	VERB
dti-1415	21	24	previous	previous	ADJ
dti-1415	21	25	conclusive	conclusive	ADJ
dti-1415	21	26	reports	report	NOUN
dti-1415	21	27	on	on	ADP
dti-1415	21	28	this	this	DET
dti-1415	21	29	reaction	reaction	NOUN
dti-1415	21	30	(	(	PUNCT
dti-1415	21	31	+1	+1	PROPN
dti-1415	21	32	)	)	PUNCT
dti-1415	21	33	,	,	PUNCT
dti-1415	21	34	the	the	DET
dti-1415	21	35	adverse	adverse	ADJ
dti-1415	21	36	even	even	ADV
dti-1415	21	37	appeared	appear	VERB
dti-1415	21	38	after	after	SCONJ
dti-1415	21	39	the	the	DET
dti-1415	21	40	suspected	suspect	VERB
dti-1415	21	41	drug	drug	NOUN
dti-1415	21	42	was	be	AUX
dti-1415	21	43	administered	administer	VERB
dti-1415	21	44	(	(	PUNCT
dti-1415	21	45	+2	+2	PROPN
dti-1415	21	46	)	)	PUNCT
dti-1415	21	47	,	,	PUNCT
dti-1415	21	48	it	it	PRON
dti-1415	21	49	improved	improve	VERB
dti-1415	21	50	after	after	SCONJ
dti-1415	21	51	the	the	DET
dti-1415	21	52	drug	drug	NOUN
dti-1415	21	53	was	be	AUX
dti-1415	21	54	discontinued	discontinue	VERB
dti-1415	21	55	(	(	PUNCT
dti-1415	21	56	+1	+1	PROPN
dti-1415	21	57	)	)	PUNCT
dti-1415	21	58	,	,	PUNCT
dti-1415	21	59	there	there	PRON
dti-1415	21	60	were	be	VERB
dti-1415	21	61	not	not	PART
dti-1415	21	62	alternative	alternative	ADJ
dti-1415	21	63	causes	cause	NOUN
dti-1415	21	64	(	(	PUNCT
dti-1415	21	65	+2)).2	+2)).2	PROPN
dti-1415	21	66	omalizumab	omalizumab	NOUN
dti-1415	21	67	is	be	AUX
dti-1415	21	68	a	a	DET
dti-1415	21	69	humanized	humanize	VERB
dti-1415	21	70	monoclonal	monoclonal	NOUN
dti-1415	21	71	anti	anti	ADJ
dti-1415	21	72	-	-	ADJ
dti-1415	21	73	ige	ige	ADJ
dti-1415	21	74	antibody	antibody	NOUN
dti-1415	21	75	indicated	indicate	VERB
dti-1415	21	76	for	for	ADP
dti-1415	21	77	the	the	DET
dti-1415	21	78	treatment	treatment	NOUN
dti-1415	21	79	of	of	ADP
dti-1415	21	80	persistent	persistent	ADJ
dti-1415	21	81	moderate	moderate	ADJ
dti-1415	21	82	-	-	PUNCT
dti-1415	21	83	to	to	ADP
dti-1415	21	84	-	-	PUNCT
dti-1415	21	85	severe	severe	ADJ
dti-1415	21	86	asthma	asthma	NOUN
dti-1415	21	87	and	and	CCONJ
dti-1415	21	88	certain	certain	ADJ
dti-1415	21	89	chronic	chronic	ADJ
dti-1415	21	90	refractory	refractory	NOUN
dti-1415	21	91	urticaria	urticaria	NOUN
dti-1415	21	92	.	.	PUNCT
dti-1415	22	1	it	it	PRON
dti-1415	22	2	has	have	AUX
dti-1415	22	3	shown	show	VERB
dti-1415	22	4	reduction	reduction	NOUN
dti-1415	22	5	in	in	ADP
dti-1415	22	6	severity	severity	NOUN
dti-1415	22	7	,	,	PUNCT
dti-1415	22	8	exacerbation	exacerbation	NOUN
dti-1415	22	9	of	of	ADP
dti-1415	22	10	symptoms	symptom	NOUN
dti-1415	22	11	,	,	PUNCT
dti-1415	22	12	and	and	CCONJ
dti-1415	22	13	the	the	DET
dti-1415	22	14	use	use	NOUN
dti-1415	22	15	of	of	ADP
dti-1415	22	16	corticosteroids	corticosteroid	NOUN
dti-1415	22	17	and	and	CCONJ
dti-1415	22	18	improvement	improvement	NOUN
dti-1415	22	19	in	in	ADP
dti-1415	22	20	quality	quality	NOUN
dti-1415	22	21	of	of	ADP
dti-1415	22	22	life	life	NOUN
dti-1415	22	23	.	.	PUNCT
dti-1415	23	1	omalizumab	omalizumab	NOUN
dti-1415	23	2	plays	play	VERB
dti-1415	23	3	a	a	DET
dti-1415	23	4	major	major	ADJ
dti-1415	23	5	role	role	NOUN
dti-1415	23	6	in	in	ADP
dti-1415	23	7	chronic	chronic	ADJ
dti-1415	23	8	allergic	allergic	ADJ
dti-1415	23	9	inflammatory	inflammatory	ADJ
dti-1415	23	10	processes	process	NOUN
dti-1415	23	11	acting	act	VERB
dti-1415	23	12	both	both	PRON
dti-1415	23	13	innate	innate	ADJ
dti-1415	23	14	and	and	CCONJ
dti-1415	23	15	humoral	humoral	ADJ
dti-1415	23	16	immunity	immunity	NOUN
dti-1415	23	17	.	.	PUNCT
dti-1415	24	1	studies	study	NOUN
dti-1415	24	2	have	have	AUX
dti-1415	24	3	shown	show	VERB
dti-1415	24	4	a	a	DET
dti-1415	24	5	link	link	NOUN
dti-1415	24	6	between	between	ADP
dti-1415	24	7	d	d	ADJ
dti-1415	24	8	-	-	PUNCT
dti-1415	24	9	dimer	dimer	ADJ
dti-1415	24	10	levels	level	NOUN
dti-1415	24	11	and	and	CCONJ
dti-1415	24	12	symptomatic	symptomatic	ADJ
dti-1415	24	13	load	load	NOUN
dti-1415	24	14	in	in	ADP
dti-1415	24	15	chronic	chronic	ADJ
dti-1415	24	16	urticaria	urticaria	NOUN
dti-1415	24	17	,	,	PUNCT
dti-1415	24	18	and	and	CCONJ
dti-1415	24	19	both	both	DET
dti-1415	24	20	features	feature	NOUN
dti-1415	24	21	improve	improve	VERB
dti-1415	24	22	in	in	ADP
dti-1415	24	23	patients	patient	NOUN
dti-1415	24	24	taking	take	VERB
dti-1415	24	25	omalizumab	omalizumab	NOUN
dti-1415	24	26	as	as	ADP
dti-1415	24	27	a	a	DET
dti-1415	24	28	provoking	provoking	ADJ
dti-1415	24	29	factor	factor	NOUN
dti-1415	24	30	for	for	ADP
dti-1415	24	31	venous	venous	ADJ
dti-1415	24	32	thromboembolism	thromboembolism	NOUN
dti-1415	24	33	crhistian	crhistian	PROPN
dti-1415	24	34	-	-	PUNCT
dti-1415	24	35	mario	mario	PROPN
dti-1415	24	36	oblitas1	oblitas1	PROPN
dti-1415	24	37	,	,	PUNCT
dti-1415	24	38	francisco	francisco	PROPN
dti-1415	24	39	galeano	galeano	PROPN
dti-1415	24	40	-	-	PUNCT
dti-1415	24	41	valle1,2	valle1,2	PROPN
dti-1415	24	42	,	,	PUNCT
dti-1415	24	43	laura	laura	PROPN
dti-1415	24	44	vela	vela	NOUN
dti-1415	24	45	-	-	PUNCT
dti-1415	24	46	de	de	X
dti-1415	24	47	la	la	X
dti-1415	24	48	cruz1	cruz1	PROPN
dti-1415	24	49	,	,	PUNCT
dti-1415	24	50	jorge	jorge	PROPN
dti-1415	24	51	del	del	PROPN
dti-1415	24	52	toro	toro	PROPN
dti-1415	24	53	-	-	PUNCT
dti-1415	24	54	cervera1,2	cervera1,2	PROPN
dti-1415	24	55	and	and	CCONJ
dti-1415	24	56	pablo	pablo	PROPN
dti-1415	24	57	demelo	demelo	PROPN
dti-1415	24	58	-	-	PUNCT
dti-1415	24	59	rodríguez1,2	rodríguez1,2	PROPN
dti-1415	24	60	1venous	1venous	NUM
dti-1415	24	61	thromboembolism	thromboembolism	NOUN
dti-1415	24	62	unit	unit	NOUN
dti-1415	24	63	,	,	PUNCT
dti-1415	24	64	hospital	hospital	PROPN
dti-1415	24	65	general	general	PROPN
dti-1415	24	66	universitario	universitario	PROPN
dti-1415	24	67	gregorio	gregorio	PROPN
dti-1415	24	68	marañón	marañón	PROPN
dti-1415	24	69	,	,	PUNCT
dti-1415	24	70	madrid	madrid	PROPN
dti-1415	24	71	,	,	PUNCT
dti-1415	24	72	spain	spain	PROPN
dti-1415	24	73	.	.	PUNCT
dti-1415	25	1	2instituto	2instituto	NUM
dti-1415	25	2	de	de	PROPN
dti-1415	25	3	investigación	investigación	PROPN
dti-1415	25	4	sanitaria	sanitaria	PROPN
dti-1415	25	5	gregorio	gregorio	PROPN
dti-1415	25	6	marañón	marañón	PROPN
dti-1415	25	7	(	(	PUNCT
dti-1415	25	8	iisgm	iisgm	PROPN
dti-1415	25	9	)	)	PUNCT
dti-1415	25	10	,	,	PUNCT
dti-1415	25	11	madrid	madrid	PROPN
dti-1415	25	12	,	,	PUNCT
dti-1415	25	13	spain	spain	PROPN
dti-1415	25	14	.	.	PUNCT
dti-1415	26	1	abstract	abstract	ADJ
dti-1415	26	2	a	a	DET
dti-1415	26	3	43	43	NUM
dti-1415	26	4	-	-	PUNCT
dti-1415	26	5	year	year	NOUN
dti-1415	26	6	-	-	PUNCT
dti-1415	26	7	old	old	ADJ
dti-1415	26	8	man	man	NOUN
dti-1415	26	9	with	with	ADP
dti-1415	26	10	a	a	DET
dti-1415	26	11	history	history	NOUN
dti-1415	26	12	of	of	ADP
dti-1415	26	13	severe	severe	ADJ
dti-1415	26	14	extrinsic	extrinsic	ADJ
dti-1415	26	15	allergic	allergic	ADJ
dti-1415	26	16	asthma	asthma	NOUN
dti-1415	26	17	treated	treat	VERB
dti-1415	26	18	with	with	ADP
dti-1415	26	19	once	once	ADV
dti-1415	26	20	-	-	PUNCT
dti-1415	26	21	monthly	monthly	ADJ
dti-1415	26	22	omalizumab	omalizumab	NOUN
dti-1415	26	23	(	(	PUNCT
dti-1415	26	24	600	600	NUM
dti-1415	26	25	mg	mg	NOUN
dti-1415	26	26	)	)	PUNCT
dti-1415	26	27	for	for	ADP
dti-1415	26	28	the	the	DET
dti-1415	26	29	last	last	ADJ
dti-1415	26	30	15	15	NUM
dti-1415	26	31	months	month	NOUN
dti-1415	26	32	.	.	PUNCT
dti-1415	27	1	he	he	PRON
dti-1415	27	2	presented	present	VERB
dti-1415	27	3	to	to	ADP
dti-1415	27	4	the	the	DET
dti-1415	27	5	emergency	emergency	NOUN
dti-1415	27	6	room	room	NOUN
dti-1415	27	7	with	with	ADP
dti-1415	27	8	a	a	DET
dti-1415	27	9	2	2	NUM
dti-1415	27	10	-	-	PUNCT
dti-1415	27	11	week	week	NOUN
dti-1415	27	12	history	history	NOUN
dti-1415	27	13	of	of	ADP
dti-1415	27	14	right	right	ADV
dti-1415	27	15	lower	low	ADJ
dti-1415	27	16	limb	limb	NOUN
dti-1415	27	17	pain	pain	NOUN
dti-1415	27	18	and	and	CCONJ
dti-1415	27	19	chest	chest	NOUN
dti-1415	27	20	pleuritic	pleuritic	ADJ
dti-1415	27	21	pain	pain	NOUN
dti-1415	27	22	.	.	PUNCT
dti-1415	28	1	computed	compute	VERB
dti-1415	28	2	tomography	tomography	NOUN
dti-1415	28	3	pulmonary	pulmonary	NOUN
dti-1415	28	4	angiography	angiography	NOUN
dti-1415	28	5	showed	show	VERB
dti-1415	28	6	bilateral	bilateral	ADJ
dti-1415	28	7	pulmonary	pulmonary	ADJ
dti-1415	28	8	embolism	embolism	NOUN
dti-1415	28	9	with	with	ADP
dti-1415	28	10	right	right	ADV
dti-1415	28	11	-	-	PUNCT
dti-1415	28	12	sided	sided	ADJ
dti-1415	28	13	pulmonary	pulmonary	ADJ
dti-1415	28	14	infarction	infarction	NOUN
dti-1415	28	15	and	and	CCONJ
dti-1415	28	16	ultrasound	ultrasound	NOUN
dti-1415	28	17	of	of	ADP
dti-1415	28	18	right	right	ADV
dti-1415	28	19	lower	low	ADJ
dti-1415	28	20	limb	limb	NOUN
dti-1415	28	21	confirmed	confirm	VERB
dti-1415	28	22	distal	distal	ADJ
dti-1415	28	23	deep	deep	ADJ
dti-1415	28	24	vein	vein	NOUN
dti-1415	28	25	thrombosis	thrombosis	NOUN
dti-1415	28	26	.	.	PUNCT
dti-1415	29	1	no	no	DET
dti-1415	29	2	other	other	ADJ
dti-1415	29	3	known	know	VERB
dti-1415	29	4	risk	risk	NOUN
dti-1415	29	5	factors	factor	NOUN
dti-1415	29	6	were	be	AUX
dti-1415	29	7	identified	identify	VERB
dti-1415	29	8	.	.	PUNCT
dti-1415	30	1	treatment	treatment	NOUN
dti-1415	30	2	with	with	ADP
dti-1415	30	3	omalizumab	omalizumab	NOUN
dti-1415	30	4	was	be	AUX
dti-1415	30	5	stopped	stop	VERB
dti-1415	30	6	during	during	ADP
dti-1415	30	7	hospitalization	hospitalization	NOUN
dti-1415	30	8	.	.	PUNCT
dti-1415	31	1	the	the	DET
dti-1415	31	2	naranjo	naranjo	PROPN
dti-1415	31	3	adverse	adverse	ADJ
dti-1415	31	4	drug	drug	NOUN
dti-1415	31	5	reaction	reaction	NOUN
dti-1415	31	6	(	(	PUNCT
dti-1415	31	7	adr	adr	PROPN
dti-1415	31	8	)	)	PUNCT
dti-1415	31	9	probability	probability	NOUN
dti-1415	31	10	scale	scale	NOUN
dti-1415	31	11	classifies	classify	VERB
dti-1415	31	12	this	this	PRON
dti-1415	31	13	as	as	ADP
dti-1415	31	14	a	a	DET
dti-1415	31	15	probable	probable	ADJ
dti-1415	31	16	adr	adr	NOUN
dti-1415	31	17	(	(	PUNCT
dti-1415	31	18	score	score	NOUN
dti-1415	31	19	of	of	ADP
dti-1415	31	20	6	6	NUM
dti-1415	31	21	)	)	PUNCT
dti-1415	31	22	.	.	PUNCT
dti-1415	32	1	omalizumab	omalizumab	NOUN
dti-1415	32	2	is	be	AUX
dti-1415	32	3	a	a	DET
dti-1415	32	4	humanized	humanize	VERB
dti-1415	32	5	monoclonal	monoclonal	NOUN
dti-1415	32	6	anti	anti	ADJ
dti-1415	32	7	-	-	ADJ
dti-1415	32	8	ige	ige	ADJ
dti-1415	32	9	antibody	antibody	NOUN
dti-1415	32	10	indicated	indicate	VERB
dti-1415	32	11	for	for	ADP
dti-1415	32	12	the	the	DET
dti-1415	32	13	treatment	treatment	NOUN
dti-1415	32	14	of	of	ADP
dti-1415	32	15	persistent	persistent	ADJ
dti-1415	32	16	moderate	moderate	ADJ
dti-1415	32	17	-	-	PUNCT
dti-1415	32	18	to	to	ADP
dti-1415	32	19	-	-	PUNCT
dti-1415	32	20	severe	severe	ADJ
dti-1415	32	21	asthma	asthma	NOUN
dti-1415	32	22	and	and	CCONJ
dti-1415	32	23	certain	certain	ADJ
dti-1415	32	24	chronic	chronic	ADJ
dti-1415	32	25	refractory	refractory	NOUN
dti-1415	32	26	urticaria	urticaria	NOUN
dti-1415	32	27	.	.	PUNCT
dti-1415	33	1	the	the	DET
dti-1415	33	2	excels	excel	NOUN
dti-1415	33	3	study	study	VERB
dti-1415	33	4	(	(	PUNCT
dti-1415	33	5	the	the	DET
dti-1415	33	6	epidemiologic	epidemiologic	ADJ
dti-1415	33	7	study	study	NOUN
dti-1415	33	8	of	of	ADP
dti-1415	33	9	xolair	xolair	PROPN
dti-1415	33	10	(	(	PUNCT
dti-1415	33	11	omalizumab	omalizumab	NOUN
dti-1415	33	12	):	):	PUNCT
dti-1415	33	13	evaluating	evaluate	VERB
dti-1415	33	14	clinical	clinical	ADJ
dti-1415	33	15	effectiveness	effectiveness	NOUN
dti-1415	33	16	and	and	CCONJ
dti-1415	33	17	long	long	ADJ
dti-1415	33	18	-	-	PUNCT
dti-1415	33	19	term	term	NOUN
dti-1415	33	20	safety	safety	NOUN
dti-1415	33	21	in	in	ADP
dti-1415	33	22	patients	patient	NOUN
dti-1415	33	23	with	with	ADP
dti-1415	33	24	moderate	moderate	ADJ
dti-1415	33	25	-	-	PUNCT
dti-1415	33	26	to	to	ADP
dti-1415	33	27	-	-	PUNCT
dti-1415	33	28	severe	severe	ADJ
dti-1415	33	29	asthma	asthma	NOUN
dti-1415	33	30	)	)	PUNCT
dti-1415	33	31	,	,	PUNCT
dti-1415	33	32	a	a	DET
dti-1415	33	33	postmarketing	postmarkete	VERB
dti-1415	33	34	observational	observational	ADJ
dti-1415	33	35	cohort	cohort	NOUN
dti-1415	33	36	study	study	NOUN
dti-1415	33	37	to	to	PART
dti-1415	33	38	assess	assess	VERB
dti-1415	33	39	clinical	clinical	ADJ
dti-1415	33	40	safety	safety	NOUN
dti-1415	33	41	profile	profile	NOUN
dti-1415	33	42	of	of	ADP
dti-1415	33	43	omalizumab	omalizumab	NOUN
dti-1415	33	44	,	,	PUNCT
dti-1415	33	45	showed	show	VERB
dti-1415	33	46	a	a	DET
dti-1415	33	47	significant	significant	ADJ
dti-1415	33	48	increase	increase	NOUN
dti-1415	33	49	in	in	ADP
dti-1415	33	50	venous	venous	ADJ
dti-1415	33	51	thromboembolism	thromboembolism	NOUN
dti-1415	33	52	.	.	PUNCT
dti-1415	34	1	in	in	ADP
dti-1415	34	2	conclusion	conclusion	NOUN
dti-1415	34	3	,	,	PUNCT
dti-1415	34	4	omalizumab	omalizumab	NOUN
dti-1415	34	5	has	have	AUX
dti-1415	34	6	been	be	AUX
dti-1415	34	7	associated	associate	VERB
dti-1415	34	8	with	with	ADP
dti-1415	34	9	arterial	arterial	NOUN
dti-1415	34	10	and	and	CCONJ
dti-1415	34	11	venous	venous	ADJ
dti-1415	34	12	thromboembolic	thromboembolic	ADJ
dti-1415	34	13	events	event	NOUN
dti-1415	34	14	,	,	PUNCT
dti-1415	34	15	although	although	SCONJ
dti-1415	34	16	the	the	DET
dti-1415	34	17	evidence	evidence	NOUN
dti-1415	34	18	is	be	AUX
dti-1415	34	19	not	not	PART
dti-1415	34	20	definitive	definitive	ADJ
dti-1415	34	21	.	.	PUNCT
dti-1415	35	1	keywords	keyword	NOUN
dti-1415	35	2	:	:	PUNCT
dti-1415	35	3	omalizumab	omalizumab	NOUN
dti-1415	35	4	,	,	PUNCT
dti-1415	35	5	venous	venous	ADJ
dti-1415	35	6	thromboembolism	thromboembolism	NOUN
dti-1415	35	7	received	receive	VERB
dti-1415	35	8	:	:	PUNCT
dti-1415	35	9	may	may	AUX
dti-1415	35	10	31	31	NUM
dti-1415	35	11	,	,	PUNCT
dti-1415	35	12	2019	2019	NUM
dti-1415	35	13	.	.	PUNCT
dti-1415	36	1	accepted	accept	VERB
dti-1415	36	2	:	:	PUNCT
dti-1415	36	3	june	june	PROPN
dti-1415	36	4	11	11	NUM
dti-1415	36	5	,	,	PUNCT
dti-1415	36	6	2019	2019	NUM
dti-1415	36	7	.	.	PUNCT
dti-1415	37	1	type	type	NOUN
dti-1415	37	2	:	:	PUNCT
dti-1415	37	3	letter	letter	NOUN
dti-1415	37	4	to	to	ADP
dti-1415	37	5	the	the	DET
dti-1415	37	6	editor	editor	NOUN
dti-1415	37	7	funding	funding	NOUN
dti-1415	37	8	:	:	PUNCT
dti-1415	37	9	the	the	DET
dti-1415	37	10	author(s	author(s	PROPN
dti-1415	37	11	)	)	PUNCT
dti-1415	37	12	received	receive	VERB
dti-1415	37	13	no	no	DET
dti-1415	37	14	financial	financial	ADJ
dti-1415	37	15	support	support	NOUN
dti-1415	37	16	for	for	ADP
dti-1415	37	17	the	the	DET
dti-1415	37	18	research	research	NOUN
dti-1415	37	19	,	,	PUNCT
dti-1415	37	20	authorship	authorship	NOUN
dti-1415	37	21	,	,	PUNCT
dti-1415	37	22	and/or	and/or	CCONJ
dti-1415	37	23	publication	publication	NOUN
dti-1415	37	24	of	of	ADP
dti-1415	37	25	this	this	DET
dti-1415	37	26	article	article	NOUN
dti-1415	37	27	.	.	PUNCT
dti-1415	38	1	declaration	declaration	NOUN
dti-1415	38	2	of	of	ADP
dti-1415	38	3	conflicting	conflicting	ADJ
dti-1415	38	4	interests	interest	NOUN
dti-1415	38	5	:	:	PUNCT
dti-1415	38	6	the	the	DET
dti-1415	38	7	author(s	author(s	NOUN
dti-1415	38	8	)	)	PUNCT
dti-1415	38	9	declared	declare	VERB
dti-1415	38	10	no	no	DET
dti-1415	38	11	potential	potential	ADJ
dti-1415	38	12	conflicts	conflict	NOUN
dti-1415	38	13	of	of	ADP
dti-1415	38	14	interest	interest	NOUN
dti-1415	38	15	with	with	ADP
dti-1415	38	16	respect	respect	NOUN
dti-1415	38	17	to	to	ADP
dti-1415	38	18	the	the	DET
dti-1415	38	19	research	research	NOUN
dti-1415	38	20	,	,	PUNCT
dti-1415	38	21	authorship	authorship	NOUN
dti-1415	38	22	,	,	PUNCT
dti-1415	38	23	and/or	and/or	CCONJ
dti-1415	38	24	publication	publication	NOUN
dti-1415	38	25	of	of	ADP
dti-1415	38	26	this	this	DET
dti-1415	38	27	article	article	NOUN
dti-1415	38	28	.	.	PUNCT
dti-1415	39	1	corresponding	correspond	VERB
dti-1415	39	2	author	author	NOUN
dti-1415	39	3	:	:	PUNCT
dti-1415	39	4	pablo	pablo	PROPN
dti-1415	39	5	demelo	demelo	PROPN
dti-1415	39	6	-	-	PUNCT
dti-1415	39	7	rodríguez	rodríguez	NOUN
dti-1415	39	8	,	,	PUNCT
dti-1415	39	9	venous	venous	ADJ
dti-1415	39	10	thromboembolism	thromboembolism	NOUN
dti-1415	39	11	unit	unit	NOUN
dti-1415	39	12	,	,	PUNCT
dti-1415	39	13	hospital	hospital	PROPN
dti-1415	39	14	general	general	PROPN
dti-1415	39	15	universitario	universitario	PROPN
dti-1415	39	16	gregorio	gregorio	PROPN
dti-1415	39	17	marañón	marañón	PROPN
dti-1415	39	18	,	,	PUNCT
dti-1415	39	19	c/.	c/.	PROPN
dti-1415	39	20	doctor	doctor	NOUN
dti-1415	39	21	esquerdo	esquerdo	PROPN
dti-1415	39	22	,	,	PUNCT
dti-1415	39	23	46	46	NUM
dti-1415	39	24	,	,	PUNCT
dti-1415	39	25	28007	28007	NUM
dti-1415	39	26	madrid	madrid	PROPN
dti-1415	39	27	,	,	PUNCT
dti-1415	39	28	spain	spain	PROPN
dti-1415	39	29	.	.	PUNCT
dti-1415	40	1	email	email	NOUN
dti-1415	40	2	:	:	PUNCT
dti-1415	41	1	pbdemelo@hotmail.com	pbdemelo@hotmail.com	X
dti-1415	41	2	861987	861987	NUM
dti-1415	41	3	dti0010.1177/1177392819861987drug	dti0010.1177/1177392819861987drug	PROPN
dti-1415	41	4	target	target	NOUN
dti-1415	41	5	insightsoblitas	insightsoblita	NOUN
dti-1415	41	6	et	et	PROPN
dti-1415	41	7	al	al	PROPN
dti-1415	41	8	letter2019	letter2019	PROPN
dti-1415	41	9	https://uk.sagepub.com/en-gb/journals-permissions	https://uk.sagepub.com/en-gb/journals-permission	NOUN
dti-1415	41	10	mailto:pbdemelo@hotmail.com	mailto:pbdemelo@hotmail.com	ADJ
dti-1415	41	11	2	2	NUM
dti-1415	41	12	drug	drug	NOUN
dti-1415	41	13	target	target	NOUN
dti-1415	41	14	insights	insight	NOUN
dti-1415	41	15	omalizumab.3,4	omalizumab.3,4	ADJ
dti-1415	41	16	the	the	DET
dti-1415	41	17	efficacy	efficacy	NOUN
dti-1415	41	18	of	of	ADP
dti-1415	41	19	omalizumab	omalizumab	NOUN
dti-1415	41	20	in	in	ADP
dti-1415	41	21	these	these	DET
dti-1415	41	22	disorders	disorder	NOUN
dti-1415	41	23	has	have	AUX
dti-1415	41	24	been	be	AUX
dti-1415	41	25	evaluated	evaluate	VERB
dti-1415	41	26	by	by	ADP
dti-1415	41	27	observing	observe	VERB
dti-1415	41	28	symptomatic	symptomatic	ADJ
dti-1415	41	29	improvement	improvement	NOUN
dti-1415	41	30	and	and	CCONJ
dti-1415	41	31	decreased	decrease	VERB
dti-1415	41	32	levels	level	NOUN
dti-1415	41	33	of	of	ADP
dti-1415	41	34	d	d	NOUN
dti-1415	41	35	-	-	PUNCT
dti-1415	41	36	dimer	dimer	ADJ
dti-1415	41	37	,	,	PUNCT
dti-1415	41	38	by	by	ADP
dti-1415	41	39	mechanisms	mechanism	NOUN
dti-1415	41	40	not	not	PART
dti-1415	41	41	well	well	ADV
dti-1415	41	42	known	known	ADJ
dti-1415	41	43	.	.	PUNCT
dti-1415	42	1	it	it	PRON
dti-1415	42	2	has	have	AUX
dti-1415	42	3	been	be	AUX
dti-1415	42	4	suggested	suggest	VERB
dti-1415	42	5	that	that	SCONJ
dti-1415	42	6	this	this	DET
dti-1415	42	7	effects	effect	NOUN
dti-1415	42	8	could	could	AUX
dti-1415	42	9	simply	simply	ADV
dti-1415	42	10	reflect	reflect	VERB
dti-1415	42	11	the	the	DET
dti-1415	42	12	reduction	reduction	NOUN
dti-1415	42	13	of	of	ADP
dti-1415	42	14	the	the	DET
dti-1415	42	15	general	general	ADJ
dti-1415	42	16	inflammatory	inflammatory	ADJ
dti-1415	42	17	state	state	NOUN
dti-1415	42	18	of	of	ADP
dti-1415	42	19	the	the	DET
dti-1415	42	20	disease	disease	NOUN
dti-1415	42	21	.	.	PUNCT
dti-1415	43	1	in	in	ADP
dti-1415	43	2	this	this	DET
dti-1415	43	3	context	context	NOUN
dti-1415	43	4	,	,	PUNCT
dti-1415	43	5	active	active	ADJ
dti-1415	43	6	chronic	chronic	ADJ
dti-1415	43	7	urticaria	urticaria	NOUN
dti-1415	43	8	and	and	CCONJ
dti-1415	43	9	persistent	persistent	ADJ
dti-1415	43	10	allergic	allergic	ADJ
dti-1415	43	11	asthma	asthma	NOUN
dti-1415	43	12	are	be	AUX
dti-1415	43	13	associated	associate	VERB
dti-1415	43	14	with	with	ADP
dti-1415	43	15	a	a	DET
dti-1415	43	16	procoagulant	procoagulant	NOUN
dti-1415	43	17	state	state	NOUN
dti-1415	43	18	by	by	ADP
dti-1415	43	19	activating	activate	VERB
dti-1415	43	20	the	the	DET
dti-1415	43	21	extrinsic	extrinsic	ADJ
dti-1415	43	22	pathway	pathway	NOUN
dti-1415	43	23	of	of	ADP
dti-1415	43	24	coagulation	coagulation	NOUN
dti-1415	43	25	in	in	ADP
dti-1415	43	26	relation	relation	NOUN
dti-1415	43	27	to	to	ADP
dti-1415	43	28	high	high	ADJ
dti-1415	43	29	levels	level	NOUN
dti-1415	43	30	of	of	ADP
dti-1415	43	31	circulatory	circulatory	ADJ
dti-1415	43	32	ige	ige	NOUN
dti-1415	43	33	,	,	PUNCT
dti-1415	43	34	molecule	molecule	NOUN
dti-1415	43	35	which	which	PRON
dti-1415	43	36	is	be	AUX
dti-1415	43	37	blocked	block	VERB
dti-1415	43	38	by	by	ADP
dti-1415	43	39	omalizumab	omalizumab	NOUN
dti-1415	43	40	reducing	reduce	VERB
dti-1415	43	41	levels	level	NOUN
dti-1415	43	42	of	of	ADP
dti-1415	43	43	d	d	NOUN
dti-1415	43	44	-	-	NOUN
dti-1415	43	45	dimer	dimer	NOUN
dti-1415	43	46	.	.	PUNCT
dti-1415	44	1	paradox	paradox	NOUN
dti-1415	44	2	ically	ically	ADV
dti-1415	44	3	,	,	PUNCT
dti-1415	44	4	it	it	PRON
dti-1415	44	5	does	do	AUX
dti-1415	44	6	not	not	PART
dti-1415	44	7	result	result	VERB
dti-1415	44	8	in	in	ADP
dti-1415	44	9	decreasing	decrease	VERB
dti-1415	44	10	the	the	DET
dti-1415	44	11	risk	risk	NOUN
dti-1415	44	12	of	of	ADP
dti-1415	44	13	vte.4,5	vte.4,5	NOUN
dti-1415	44	14	the	the	DET
dti-1415	44	15	d	d	ADJ
dti-1415	44	16	-	-	PUNCT
dti-1415	44	17	dimer	dimer	ADJ
dti-1415	44	18	levels	level	NOUN
dti-1415	44	19	are	be	AUX
dti-1415	44	20	considered	consider	VERB
dti-1415	44	21	to	to	PART
dti-1415	44	22	be	be	AUX
dti-1415	44	23	useful	useful	ADJ
dti-1415	44	24	for	for	ADP
dti-1415	44	25	the	the	DET
dti-1415	44	26	diagnosis	diagnosis	NOUN
dti-1415	44	27	of	of	ADP
dti-1415	44	28	thrombosis	thrombosis	NOUN
dti-1415	44	29	,	,	PUNCT
dti-1415	44	30	and	and	CCONJ
dti-1415	44	31	they	they	PRON
dti-1415	44	32	can	can	AUX
dti-1415	44	33	be	be	AUX
dti-1415	44	34	clinically	clinically	ADV
dti-1415	44	35	used	use	VERB
dti-1415	44	36	due	due	ADP
dti-1415	44	37	to	to	ADP
dti-1415	44	38	its	its	PRON
dti-1415	44	39	high	high	ADJ
dti-1415	44	40	negative	negative	ADJ
dti-1415	44	41	predictive	predictive	ADJ
dti-1415	44	42	value	value	NOUN
dti-1415	44	43	.	.	PUNCT
dti-1415	45	1	hence	hence	ADV
dti-1415	45	2	,	,	PUNCT
dti-1415	45	3	the	the	DET
dti-1415	45	4	decrease	decrease	NOUN
dti-1415	45	5	in	in	ADP
dti-1415	45	6	d	d	ADJ
dti-1415	45	7	-	-	PUNCT
dti-1415	45	8	dimer	dimer	ADJ
dti-1415	45	9	levels	level	NOUN
dti-1415	45	10	could	could	AUX
dti-1415	45	11	mask	mask	VERB
dti-1415	45	12	its	its	PRON
dti-1415	45	13	diagnostic	diagnostic	ADJ
dti-1415	45	14	predictive	predictive	ADJ
dti-1415	45	15	value	value	NOUN
dti-1415	45	16	in	in	ADP
dti-1415	45	17	cases	case	NOUN
dti-1415	45	18	of	of	ADP
dti-1415	45	19	vte	vte	NOUN
dti-1415	45	20	in	in	ADP
dti-1415	45	21	patients	patient	NOUN
dti-1415	45	22	receiving	receive	VERB
dti-1415	45	23	omalizumab	omalizumab	NOUN
dti-1415	45	24	.	.	PUNCT
dti-1415	46	1	recently	recently	ADV
dti-1415	46	2	,	,	PUNCT
dti-1415	46	3	some	some	DET
dti-1415	46	4	articles	article	NOUN
dti-1415	46	5	reporting	report	VERB
dti-1415	46	6	the	the	DET
dti-1415	46	7	association	association	NOUN
dti-1415	46	8	of	of	ADP
dti-1415	46	9	omalizumab	omalizumab	NOUN
dti-1415	46	10	with	with	ADP
dti-1415	46	11	pulmonary	pulmonary	ADJ
dti-1415	46	12	vein	vein	NOUN
dti-1415	46	13	thrombosis6	thrombosis6	NOUN
dti-1415	46	14	and	and	CCONJ
dti-1415	46	15	some	some	DET
dti-1415	46	16	studies	study	NOUN
dti-1415	46	17	evaluating	evaluate	VERB
dti-1415	46	18	the	the	DET
dti-1415	46	19	long	long	ADJ
dti-1415	46	20	-	-	PUNCT
dti-1415	46	21	term	term	NOUN
dti-1415	46	22	use	use	NOUN
dti-1415	46	23	of	of	ADP
dti-1415	46	24	omalizumab	omalizumab	NOUN
dti-1415	46	25	have	have	AUX
dti-1415	46	26	been	be	AUX
dti-1415	46	27	published	publish	VERB
dti-1415	46	28	.	.	PUNCT
dti-1415	47	1	the	the	DET
dti-1415	47	2	most	most	ADV
dti-1415	47	3	important	important	ADJ
dti-1415	47	4	study	study	NOUN
dti-1415	47	5	to	to	ADP
dti-1415	47	6	date	date	NOUN
dti-1415	47	7	is	be	AUX
dti-1415	47	8	the	the	DET
dti-1415	47	9	excels	excel	NOUN
dti-1415	47	10	study	study	VERB
dti-1415	47	11	,	,	PUNCT
dti-1415	47	12	a	a	DET
dti-1415	47	13	postmarketing	postmarkete	VERB
dti-1415	47	14	5	5	NUM
dti-1415	47	15	-	-	PUNCT
dti-1415	47	16	year	year	NOUN
dti-1415	47	17	follow	follow	NOUN
dti-1415	47	18	-	-	PUNCT
dti-1415	47	19	up	up	ADP
dti-1415	47	20	observational	observational	ADJ
dti-1415	47	21	cohort	cohort	NOUN
dti-1415	47	22	study	study	NOUN
dti-1415	47	23	to	to	PART
dti-1415	47	24	assess	assess	VERB
dti-1415	47	25	clinical	clinical	ADJ
dti-1415	47	26	safety	safety	NOUN
dti-1415	47	27	profile	profile	NOUN
dti-1415	47	28	of	of	ADP
dti-1415	47	29	omalizumab	omalizumab	NOUN
dti-1415	47	30	(	(	PUNCT
dti-1415	47	31	7857	7857	NUM
dti-1415	47	32	patients	patient	NOUN
dti-1415	47	33	were	be	AUX
dti-1415	47	34	included	include	VERB
dti-1415	47	35	)	)	PUNCT
dti-1415	47	36	.	.	PUNCT
dti-1415	48	1	this	this	DET
dti-1415	48	2	study	study	NOUN
dti-1415	48	3	,	,	PUNCT
dti-1415	48	4	primarily	primarily	ADV
dti-1415	48	5	designed	design	VERB
dti-1415	48	6	for	for	ADP
dti-1415	48	7	the	the	DET
dti-1415	48	8	detection	detection	NOUN
dti-1415	48	9	of	of	ADP
dti-1415	48	10	malignancies	malignancy	NOUN
dti-1415	48	11	,	,	PUNCT
dti-1415	48	12	showed	show	VERB
dti-1415	48	13	an	an	DET
dti-1415	48	14	increased	increase	VERB
dti-1415	48	15	risk	risk	NOUN
dti-1415	48	16	in	in	ADP
dti-1415	48	17	vte	vte	NOUN
dti-1415	48	18	(	(	PUNCT
dti-1415	48	19	crude	crude	ADJ
dti-1415	48	20	incidence	incidence	NOUN
dti-1415	48	21	rate	rate	NOUN
dti-1415	48	22	=	=	NOUN
dti-1415	48	23	3.2	3.2	NUM
dti-1415	48	24	[	[	SYM
dti-1415	48	25	95	95	NUM
dti-1415	48	26	%	%	NOUN
dti-1415	48	27	ci	ci	NOUN
dti-1415	49	1	=	=	NOUN
dti-1415	50	1	2.4	2.4	NUM
dti-1415	50	2	-	-	SYM
dti-1415	50	3	4.3	4.3	NUM
dti-1415	50	4	]	]	PUNCT
dti-1415	50	5	vs	vs	ADP
dti-1415	50	6	1.5	1.5	NUM
dti-1415	50	7	[	[	SYM
dti-1415	50	8	95	95	NUM
dti-1415	50	9	%	%	NOUN
dti-1415	50	10	ci	ci	NOUN
dti-1415	50	11	=	=	SYM
dti-1415	50	12	0.82.5	0.82.5	NUM
dti-1415	50	13	]	]	X
dti-1415	50	14	per	per	ADP
dti-1415	50	15	1000	1000	NUM
dti-1415	50	16	person	person	NOUN
dti-1415	50	17	-	-	PUNCT
dti-1415	50	18	years	year	NOUN
dti-1415	50	19	)	)	PUNCT
dti-1415	50	20	.	.	PUNCT
dti-1415	51	1	the	the	DET
dti-1415	51	2	incidence	incidence	NOUN
dti-1415	51	3	rate	rate	NOUN
dti-1415	51	4	of	of	ADP
dti-1415	51	5	primary	primary	ADJ
dti-1415	51	6	neoplasms	neoplasm	NOUN
dti-1415	51	7	was	be	AUX
dti-1415	51	8	similar	similar	ADJ
dti-1415	51	9	in	in	ADP
dti-1415	51	10	both	both	DET
dti-1415	51	11	groups.7	groups.7	NOUN
dti-1415	51	12	consequently	consequently	ADV
dti-1415	51	13	,	,	PUNCT
dti-1415	51	14	the	the	DET
dti-1415	51	15	us	us	PROPN
dti-1415	51	16	food	food	NOUN
dti-1415	51	17	and	and	CCONJ
dti-1415	51	18	drug	drug	NOUN
dti-1415	51	19	administration8	administration8	PROPN
dti-1415	51	20	published	publish	VERB
dti-1415	51	21	a	a	DET
dti-1415	51	22	drug	drug	NOUN
dti-1415	51	23	safety	safety	NOUN
dti-1415	51	24	communication	communication	NOUN
dti-1415	51	25	on	on	ADP
dti-1415	51	26	september	september	PROPN
dti-1415	51	27	26	26	NUM
dti-1415	51	28	,	,	PUNCT
dti-1415	51	29	2014	2014	NUM
dti-1415	51	30	,	,	PUNCT
dti-1415	51	31	describing	describe	VERB
dti-1415	51	32	slightly	slightly	ADV
dti-1415	51	33	higher	high	ADJ
dti-1415	51	34	risk	risk	NOUN
dti-1415	51	35	of	of	ADP
dti-1415	51	36	blood	blood	NOUN
dti-1415	51	37	clots	clot	NOUN
dti-1415	51	38	in	in	ADP
dti-1415	51	39	the	the	DET
dti-1415	51	40	lungs	lung	NOUN
dti-1415	51	41	and	and	CCONJ
dti-1415	51	42	veins	vein	NOUN
dti-1415	51	43	,	,	PUNCT
dti-1415	51	44	in	in	ADP
dti-1415	51	45	addition	addition	NOUN
dti-1415	51	46	to	to	ADP
dti-1415	51	47	heart	heart	NOUN
dti-1415	51	48	and	and	CCONJ
dti-1415	51	49	brain	brain	VERB
dti-1415	51	50	adverse	adverse	ADJ
dti-1415	51	51	events	event	NOUN
dti-1415	51	52	.	.	PUNCT
dti-1415	52	1	however	however	ADV
dti-1415	52	2	,	,	PUNCT
dti-1415	52	3	conflicting	conflicting	ADJ
dti-1415	52	4	results	result	NOUN
dti-1415	52	5	of	of	ADP
dti-1415	52	6	other	other	ADJ
dti-1415	52	7	recent	recent	ADJ
dti-1415	52	8	studies	study	NOUN
dti-1415	52	9	have	have	AUX
dti-1415	52	10	been	be	AUX
dti-1415	52	11	published	publish	VERB
dti-1415	52	12	.	.	PUNCT
dti-1415	53	1	a	a	DET
dti-1415	53	2	letter	letter	NOUN
dti-1415	53	3	reported	report	VERB
dti-1415	53	4	results	result	NOUN
dti-1415	53	5	from	from	ADP
dti-1415	53	6	a	a	DET
dti-1415	53	7	pooled	pooled	ADJ
dti-1415	53	8	analysis	analysis	NOUN
dti-1415	53	9	of	of	ADP
dti-1415	53	10	cardiovascular	cardiovascular	ADJ
dti-1415	53	11	events	event	NOUN
dti-1415	53	12	from	from	ADP
dti-1415	53	13	25	25	NUM
dti-1415	53	14	randomized	randomized	ADJ
dti-1415	53	15	controlled	control	VERB
dti-1415	53	16	trials	trial	NOUN
dti-1415	53	17	and	and	CCONJ
dti-1415	53	18	2	2	NUM
dti-1415	53	19	extension	extension	NOUN
dti-1415	53	20	studies	study	NOUN
dti-1415	53	21	of	of	ADP
dti-1415	53	22	omalizumab	omalizumab	NOUN
dti-1415	53	23	.	.	PUNCT
dti-1415	54	1	this	this	DET
dti-1415	54	2	analysis	analysis	NOUN
dti-1415	54	3	did	do	AUX
dti-1415	54	4	not	not	PART
dti-1415	54	5	find	find	VERB
dti-1415	54	6	any	any	DET
dti-1415	54	7	differences	difference	NOUN
dti-1415	54	8	in	in	ADP
dti-1415	54	9	the	the	DET
dti-1415	54	10	incidence	incidence	NOUN
dti-1415	54	11	of	of	ADP
dti-1415	54	12	vte	vte	NOUN
dti-1415	54	13	between	between	ADP
dti-1415	54	14	omalizumab	omalizumab	NOUN
dti-1415	54	15	or	or	CCONJ
dti-1415	54	16	placebo.9	placebo.9	ADJ
dti-1415	54	17	there	there	PRON
dti-1415	54	18	are	be	VERB
dti-1415	54	19	no	no	DET
dti-1415	54	20	specific	specific	ADJ
dti-1415	54	21	recommendations	recommendation	NOUN
dti-1415	54	22	for	for	ADP
dti-1415	54	23	patients	patient	NOUN
dti-1415	54	24	who	who	PRON
dti-1415	54	25	suffer	suffer	VERB
dti-1415	54	26	a	a	DET
dti-1415	54	27	vte	vte	NOUN
dti-1415	54	28	event	event	NOUN
dti-1415	54	29	under	under	ADP
dti-1415	54	30	treatment	treatment	NOUN
dti-1415	54	31	with	with	ADP
dti-1415	54	32	omalizumab	omalizumab	NOUN
dti-1415	54	33	,	,	PUNCT
dti-1415	54	34	but	but	CCONJ
dti-1415	54	35	if	if	SCONJ
dti-1415	54	36	we	we	PRON
dti-1415	54	37	consider	consider	VERB
dti-1415	54	38	it	it	PRON
dti-1415	54	39	as	as	ADP
dti-1415	54	40	a	a	DET
dti-1415	54	41	temporary	temporary	ADJ
dti-1415	54	42	risk	risk	NOUN
dti-1415	54	43	factor	factor	NOUN
dti-1415	54	44	for	for	ADP
dti-1415	54	45	vte	vte	NOUN
dti-1415	54	46	,	,	PUNCT
dti-1415	54	47	we	we	PRON
dti-1415	54	48	suggest	suggest	VERB
dti-1415	54	49	drug	drug	NOUN
dti-1415	54	50	withdrawal	withdrawal	NOUN
dti-1415	54	51	and	and	CCONJ
dti-1415	54	52	anticoagulation	anticoagulation	NOUN
dti-1415	54	53	for	for	ADP
dti-1415	54	54	at	at	ADV
dti-1415	54	55	least	least	ADV
dti-1415	54	56	6	6	NUM
dti-1415	54	57	months	month	NOUN
dti-1415	54	58	in	in	ADP
dti-1415	54	59	the	the	DET
dti-1415	54	60	absence	absence	NOUN
dti-1415	54	61	of	of	ADP
dti-1415	54	62	other	other	ADJ
dti-1415	54	63	risk	risk	NOUN
dti-1415	54	64	factors.10	factors.10	NOUN
dti-1415	54	65	because	because	SCONJ
dti-1415	54	66	omalizumab	omalizumab	NOUN
dti-1415	54	67	is	be	AUX
dti-1415	54	68	administered	administer	VERB
dti-1415	54	69	in	in	ADP
dti-1415	54	70	a	a	DET
dti-1415	54	71	health	health	NOUN
dti-1415	54	72	care	care	NOUN
dti-1415	54	73	setting	setting	NOUN
dti-1415	54	74	,	,	PUNCT
dti-1415	54	75	it	it	PRON
dti-1415	54	76	may	may	AUX
dti-1415	54	77	not	not	PART
dti-1415	54	78	be	be	AUX
dti-1415	54	79	listed	list	VERB
dti-1415	54	80	on	on	ADP
dti-1415	54	81	the	the	DET
dti-1415	54	82	patient	patient	NOUN
dti-1415	54	83	’s	’s	PART
dti-1415	54	84	home	home	NOUN
dti-1415	54	85	medication	medication	NOUN
dti-1415	54	86	list	list	NOUN
dti-1415	54	87	,	,	PUNCT
dti-1415	54	88	and	and	CCONJ
dti-1415	54	89	therefore	therefore	ADV
dti-1415	54	90	,	,	PUNCT
dti-1415	54	91	physicians	physician	NOUN
dti-1415	54	92	and	and	CCONJ
dti-1415	54	93	pharmacists	pharmacist	NOUN
dti-1415	54	94	should	should	AUX
dti-1415	54	95	evaluate	evaluate	VERB
dti-1415	54	96	clinicadministered	clinicadministere	VERB
dti-1415	54	97	medication	medication	NOUN
dti-1415	54	98	when	when	SCONJ
dti-1415	54	99	evaluating	evaluate	VERB
dti-1415	54	100	vte	vte	NOUN
dti-1415	54	101	risk	risk	NOUN
dti-1415	54	102	factors	factor	NOUN
dti-1415	54	103	.	.	PUNCT
dti-1415	55	1	in	in	ADP
dti-1415	55	2	conclusion	conclusion	NOUN
dti-1415	55	3	,	,	PUNCT
dti-1415	55	4	omalizumab	omalizumab	NOUN
dti-1415	55	5	has	have	AUX
dti-1415	55	6	been	be	AUX
dti-1415	55	7	associated	associate	VERB
dti-1415	55	8	with	with	ADP
dti-1415	55	9	arterial	arterial	NOUN
dti-1415	55	10	and	and	CCONJ
dti-1415	55	11	venous	venous	ADJ
dti-1415	55	12	thromboembolic	thromboembolic	ADJ
dti-1415	55	13	events	event	NOUN
dti-1415	55	14	,	,	PUNCT
dti-1415	55	15	although	although	SCONJ
dti-1415	55	16	the	the	DET
dti-1415	55	17	evidence	evidence	NOUN
dti-1415	55	18	is	be	AUX
dti-1415	55	19	not	not	PART
dti-1415	55	20	definitive	definitive	ADJ
dti-1415	55	21	.	.	PUNCT
dti-1415	56	1	it	it	PRON
dti-1415	56	2	has	have	AUX
dti-1415	56	3	been	be	AUX
dti-1415	56	4	associated	associate	VERB
dti-1415	56	5	with	with	ADP
dti-1415	56	6	decrease	decrease	NOUN
dti-1415	56	7	in	in	ADP
dti-1415	56	8	d	d	ADJ
dti-1415	56	9	-	-	PUNCT
dti-1415	56	10	dimer	dimer	ADJ
dti-1415	56	11	levels	level	NOUN
dti-1415	56	12	that	that	PRON
dti-1415	56	13	could	could	AUX
dti-1415	56	14	mask	mask	VERB
dti-1415	56	15	its	its	PRON
dti-1415	56	16	diagnostic	diagnostic	ADJ
dti-1415	56	17	predictive	predictive	ADJ
dti-1415	56	18	value	value	NOUN
dti-1415	56	19	.	.	PUNCT
dti-1415	57	1	we	we	PRON
dti-1415	57	2	point	point	VERB
dti-1415	57	3	out	out	ADP
dti-1415	57	4	the	the	DET
dti-1415	57	5	need	need	NOUN
dti-1415	57	6	for	for	ADP
dti-1415	57	7	studies	study	NOUN
dti-1415	57	8	that	that	PRON
dti-1415	57	9	clarify	clarify	VERB
dti-1415	57	10	the	the	DET
dti-1415	57	11	role	role	NOUN
dti-1415	57	12	of	of	ADP
dti-1415	57	13	omalizumab	omalizumab	NOUN
dti-1415	57	14	in	in	ADP
dti-1415	57	15	the	the	DET
dti-1415	57	16	setting	setting	NOUN
dti-1415	57	17	of	of	ADP
dti-1415	57	18	vte	vte	NOUN
dti-1415	57	19	.	.	PUNCT
dti-1415	58	1	author	author	NOUN
dti-1415	58	2	contributions	contribution	NOUN
dti-1415	58	3	all	all	DET
dti-1415	58	4	authors	author	NOUN
dti-1415	58	5	contributed	contribute	VERB
dti-1415	58	6	equally	equally	ADV
dti-1415	58	7	to	to	ADP
dti-1415	58	8	the	the	DET
dti-1415	58	9	colletion	colletion	NOUN
dti-1415	58	10	of	of	ADP
dti-1415	58	11	data	datum	NOUN
dti-1415	58	12	,	,	PUNCT
dti-1415	58	13	analysis	analysis	NOUN
dti-1415	58	14	and	and	CCONJ
dti-1415	58	15	interpretation	interpretation	NOUN
dti-1415	58	16	,	,	PUNCT
dti-1415	58	17	manuscript	manuscript	NOUN
dti-1415	58	18	writing	writing	NOUN
dti-1415	58	19	and	and	CCONJ
dti-1415	58	20	final	final	ADJ
dti-1415	58	21	approval	approval	NOUN
dti-1415	58	22	of	of	ADP
dti-1415	58	23	manuscript	manuscript	NOUN
dti-1415	58	24	.	.	PUNCT
dti-1415	59	1	informed	informed	ADJ
dti-1415	59	2	consent	consent	NOUN
dti-1415	59	3	we	we	PRON
dti-1415	59	4	obtained	obtain	VERB
dti-1415	59	5	the	the	DET
dti-1415	59	6	patient	patient	NOUN
dti-1415	59	7	’s	’s	PART
dti-1415	59	8	written	write	VERB
dti-1415	59	9	informed	informed	ADJ
dti-1415	59	10	consent	consent	NOUN
dti-1415	59	11	before	before	ADP
dti-1415	59	12	the	the	DET
dti-1415	59	13	submission	submission	NOUN
dti-1415	59	14	of	of	ADP
dti-1415	59	15	the	the	DET
dti-1415	59	16	letter	letter	NOUN
dti-1415	59	17	.	.	PUNCT
dti-1415	60	1	orcid	orcid	NOUN
dti-1415	61	1	i	i	PROPN
dti-1415	61	2	d	d	PROPN
dti-1415	61	3	francisco	francisco	PROPN
dti-1415	61	4	galeano	galeano	NOUN
dti-1415	61	5	-	-	PUNCT
dti-1415	61	6	valle	valle	NOUN
dti-1415	61	7	https://orcid.org/0000-0003-1321	https://orcid.org/0000-0003-1321	PROPN
dti-1415	61	8	-6866	-6866	PROPN
dti-1415	61	9	references	reference	NOUN
dti-1415	61	10	1	1	NUM
dti-1415	61	11	.	.	PUNCT
dti-1415	61	12	tritschler	tritschler	PROPN
dti-1415	61	13	t	t	PROPN
dti-1415	61	14	,	,	PUNCT
dti-1415	61	15	kraaijpoel	kraaijpoel	PROPN
dti-1415	61	16	n	n	CCONJ
dti-1415	61	17	,	,	PUNCT
dti-1415	62	1	le	le	X
dti-1415	62	2	gal	gal	PROPN
dti-1415	62	3	g	g	PROPN
dti-1415	62	4	,	,	PUNCT
dti-1415	62	5	wells	wells	PROPN
dti-1415	62	6	ps	ps	PROPN
dti-1415	62	7	.	.	PROPN
dti-1415	62	8	venous	venous	ADJ
dti-1415	62	9	thromboembolism	thromboembolism	NOUN
dti-1415	62	10	:	:	PUNCT
dti-1415	62	11	advances	advance	NOUN
dti-1415	62	12	in	in	ADP
dti-1415	62	13	diagnosis	diagnosis	NOUN
dti-1415	62	14	and	and	CCONJ
dti-1415	62	15	treatment	treatment	NOUN
dti-1415	62	16	.	.	PUNCT
dti-1415	63	1	jama	jama	PROPN
dti-1415	63	2	.	.	PUNCT
dti-1415	64	1	2018;320:1583–1594	2018;320:1583–1594	X
dti-1415	64	2	.	.	NOUN
dti-1415	65	1	2	2	NUM
dti-1415	65	2	.	.	X
dti-1415	65	3	naranjo	naranjo	PROPN
dti-1415	65	4	ca	ca	PROPN
dti-1415	65	5	,	,	PUNCT
dti-1415	65	6	busto	busto	NOUN
dti-1415	65	7	u	u	NOUN
dti-1415	65	8	,	,	PUNCT
dti-1415	65	9	sellers	seller	VERB
dti-1415	65	10	em	em	PRON
dti-1415	65	11	,	,	PUNCT
dti-1415	65	12	sandor	sandor	PROPN
dti-1415	65	13	p	p	PROPN
dti-1415	65	14	,	,	PUNCT
dti-1415	65	15	ruiz	ruiz	NOUN
dti-1415	65	16	i	i	PROPN
dti-1415	65	17	,	,	PUNCT
dti-1415	65	18	roberts	roberts	PROPN
dti-1415	65	19	ea	ea	PROPN
dti-1415	65	20	.	.	PUNCT
dti-1415	66	1	a	a	DET
dti-1415	66	2	method	method	NOUN
dti-1415	66	3	for	for	ADP
dti-1415	66	4	estimating	estimate	VERB
dti-1415	66	5	the	the	DET
dti-1415	66	6	probability	probability	NOUN
dti-1415	66	7	of	of	ADP
dti-1415	66	8	adverse	adverse	ADJ
dti-1415	66	9	drug	drug	NOUN
dti-1415	66	10	reactions	reaction	NOUN
dti-1415	66	11	.	.	PUNCT
dti-1415	67	1	clin	clin	PROPN
dti-1415	67	2	pharmacol	pharmacol	PROPN
dti-1415	67	3	ther	ther	ADV
dti-1415	67	4	.	.	PUNCT
dti-1415	68	1	1981;30:239–245	1981;30:239–245	X
dti-1415	68	2	.	.	PUNCT
dti-1415	69	1	3	3	X
dti-1415	69	2	.	.	X
dti-1415	69	3	d’amato	d’amato	VERB
dti-1415	69	4	g	g	NOUN
dti-1415	69	5	,	,	PUNCT
dti-1415	69	6	stanziola	stanziola	PROPN
dti-1415	69	7	a	a	PRON
dti-1415	69	8	,	,	PUNCT
dti-1415	69	9	sanduzzi	sanduzzi	ADV
dti-1415	69	10	a	a	X
dti-1415	69	11	,	,	PUNCT
dti-1415	69	12	et	et	PROPN
dti-1415	69	13	al	al	PROPN
dti-1415	69	14	.	.	PUNCT
dti-1415	70	1	treating	treat	VERB
dti-1415	70	2	severe	severe	ADJ
dti-1415	70	3	allergic	allergic	ADJ
dti-1415	70	4	asthma	asthma	NOUN
dti-1415	70	5	with	with	ADP
dti-1415	70	6	anti	anti	ADJ
dti-1415	70	7	-	-	ADJ
dti-1415	70	8	ige	ige	ADJ
dti-1415	70	9	monoclonal	monoclonal	NOUN
dti-1415	70	10	antibody	antibody	NOUN
dti-1415	70	11	(	(	PUNCT
dti-1415	70	12	omalizumab	omalizumab	NOUN
dti-1415	70	13	):	):	PUNCT
dti-1415	70	14	a	a	DET
dti-1415	70	15	review	review	NOUN
dti-1415	70	16	.	.	PUNCT
dti-1415	71	1	multidiscip	multidiscip	NOUN
dti-1415	71	2	respir	respir	VERB
dti-1415	71	3	med	med	ADJ
dti-1415	71	4	.	.	PUNCT
dti-1415	71	5	2014;9:23	2014;9:23	NOUN
dti-1415	71	6	.	.	PUNCT
dti-1415	72	1	4	4	X
dti-1415	72	2	.	.	X
dti-1415	72	3	asero	asero	PROPN
dti-1415	72	4	r.	r.	PROPN
dti-1415	72	5	serial	serial	PROPN
dti-1415	72	6	d	d	ADJ
dti-1415	72	7	-	-	PUNCT
dti-1415	72	8	dimer	dimer	ADJ
dti-1415	72	9	plasma	plasma	NOUN
dti-1415	72	10	levels	level	NOUN
dti-1415	72	11	in	in	ADP
dti-1415	72	12	a	a	DET
dti-1415	72	13	patient	patient	NOUN
dti-1415	72	14	with	with	ADP
dti-1415	72	15	chronic	chronic	ADJ
dti-1415	72	16	spontaneous	spontaneous	ADJ
dti-1415	72	17	urticaria	urticaria	NOUN
dti-1415	72	18	developing	develop	VERB
dti-1415	72	19	resistance	resistance	NOUN
dti-1415	72	20	to	to	ADP
dti-1415	72	21	omalizumab	omalizumab	NOUN
dti-1415	72	22	.	.	PUNCT
dti-1415	73	1	clin	clin	PROPN
dti-1415	73	2	exp	exp	NOUN
dti-1415	73	3	dermatol	dermatol	NOUN
dti-1415	73	4	.	.	PUNCT
dti-1415	74	1	2017;42:667–669	2017;42:667–669	NOUN
dti-1415	74	2	.	.	PUNCT
dti-1415	75	1	5	5	NUM
dti-1415	75	2	.	.	X
dti-1415	75	3	yalcin	yalcin	PROPN
dti-1415	75	4	ad	ad	NOUN
dti-1415	75	5	,	,	PUNCT
dti-1415	75	6	celik	celik	VERB
dti-1415	75	7	b	b	NUM
dti-1415	75	8	,	,	PUNCT
dti-1415	75	9	gumuslu	gumuslu	NOUN
dti-1415	75	10	s.	s.	PROPN
dti-1415	75	11	d	d	PROPN
dti-1415	75	12	-	-	PUNCT
dti-1415	75	13	dimer	dimer	ADJ
dti-1415	75	14	levels	level	NOUN
dti-1415	75	15	decreased	decrease	VERB
dti-1415	75	16	in	in	ADP
dti-1415	75	17	severe	severe	ADJ
dti-1415	75	18	allergic	allergic	ADJ
dti-1415	75	19	asthma	asthma	NOUN
dti-1415	75	20	and	and	CCONJ
dti-1415	75	21	chronic	chronic	ADJ
dti-1415	75	22	urticaria	urticaria	NOUN
dti-1415	75	23	patients	patient	NOUN
dti-1415	75	24	with	with	ADP
dti-1415	75	25	the	the	DET
dti-1415	75	26	omalizumab	omalizumab	NOUN
dti-1415	75	27	treatment	treatment	NOUN
dti-1415	75	28	.	.	PUNCT
dti-1415	76	1	expert	expert	NOUN
dti-1415	76	2	opin	opin	NOUN
dti-1415	76	3	biol	biol	NOUN
dti-1415	76	4	ther	ther	ADV
dti-1415	76	5	.	.	PUNCT
dti-1415	77	1	2014;14:283–286	2014;14:283–286	ADJ
dti-1415	77	2	.	.	PUNCT
dti-1415	78	1	6	6	NUM
dti-1415	78	2	.	.	X
dti-1415	79	1	narukonda	narukonda	PROPN
dti-1415	79	2	s	s	PROPN
dti-1415	79	3	,	,	PUNCT
dti-1415	79	4	vinod	vinod	PROPN
dti-1415	79	5	nr	nr	PROPN
dti-1415	79	6	,	,	PUNCT
dti-1415	79	7	joshi	joshi	PROPN
dti-1415	79	8	m.	m.	PROPN
dti-1415	79	9	a	a	DET
dti-1415	79	10	case	case	NOUN
dti-1415	79	11	of	of	ADP
dti-1415	79	12	pulmonary	pulmonary	ADJ
dti-1415	79	13	vein	vein	NOUN
dti-1415	79	14	thrombosis	thrombosis	NOUN
dti-1415	79	15	associated	associate	VERB
dti-1415	79	16	with	with	ADP
dti-1415	79	17	treatment	treatment	NOUN
dti-1415	79	18	of	of	ADP
dti-1415	79	19	omalizumab	omalizumab	NOUN
dti-1415	79	20	.	.	PUNCT
dti-1415	80	1	j	j	PROPN
dti-1415	80	2	investig	investig	NOUN
dti-1415	80	3	med	med	ADJ
dti-1415	80	4	high	high	ADJ
dti-1415	80	5	impact	impact	NOUN
dti-1415	80	6	case	case	NOUN
dti-1415	80	7	rep	rep	PROPN
dti-1415	80	8	.	.	PROPN
dti-1415	80	9	2017;5:2324709617724176	2017;5:2324709617724176	PROPN
dti-1415	80	10	.	.	PUNCT
dti-1415	81	1	7	7	X
dti-1415	81	2	.	.	X
dti-1415	81	3	iribarren	iribarren	PROPN
dti-1415	81	4	c	c	NOUN
dti-1415	81	5	,	,	PUNCT
dti-1415	81	6	rahmaoui	rahmaoui	ADV
dti-1415	81	7	a	a	DET
dti-1415	81	8	,	,	PUNCT
dti-1415	81	9	long	long	ADJ
dti-1415	81	10	aa	aa	NOUN
dti-1415	81	11	,	,	PUNCT
dti-1415	81	12	et	et	PROPN
dti-1415	81	13	al	al	PROPN
dti-1415	81	14	.	.	PUNCT
dti-1415	82	1	cardiovascular	cardiovascular	ADJ
dti-1415	82	2	and	and	CCONJ
dti-1415	82	3	cerebrovascular	cerebrovascular	ADJ
dti-1415	82	4	events	event	NOUN
dti-1415	82	5	among	among	ADP
dti-1415	82	6	patients	patient	NOUN
dti-1415	82	7	receiving	receive	VERB
dti-1415	82	8	omalizumab	omalizumab	NOUN
dti-1415	82	9	:	:	PUNCT
dti-1415	82	10	results	result	NOUN
dti-1415	82	11	from	from	ADP
dti-1415	82	12	excels	excel	NOUN
dti-1415	82	13	,	,	PUNCT
dti-1415	82	14	a	a	DET
dti-1415	82	15	prospective	prospective	ADJ
dti-1415	82	16	cohort	cohort	NOUN
dti-1415	82	17	study	study	NOUN
dti-1415	82	18	in	in	ADP
dti-1415	82	19	moderate	moderate	ADJ
dti-1415	82	20	to	to	ADP
dti-1415	82	21	severe	severe	ADJ
dti-1415	82	22	asthma	asthma	NOUN
dti-1415	82	23	.	.	PUNCT
dti-1415	83	1	j	j	PROPN
dti-1415	83	2	allergy	allergy	PROPN
dti-1415	83	3	clin	clin	PROPN
dti-1415	83	4	immunol	immunol	NOUN
dti-1415	83	5	.	.	PUNCT
dti-1415	84	1	2017;139:1489.e5–1495.e5	2017;139:1489.e5–1495.e5	NUM
dti-1415	84	2	.	.	X
dti-1415	84	3	8	8	NUM
dti-1415	84	4	.	.	X
dti-1415	84	5	us	us	PROPN
dti-1415	84	6	food	food	NOUN
dti-1415	84	7	and	and	CCONJ
dti-1415	84	8	drug	drug	NOUN
dti-1415	84	9	administration	administration	NOUN
dti-1415	84	10	.	.	PUNCT
dti-1415	85	1	fda	fda	PROPN
dti-1415	85	2	drug	drug	PROPN
dti-1415	85	3	safety	safety	NOUN
dti-1415	85	4	communication	communication	NOUN
dti-1415	85	5	:	:	PUNCT
dti-1415	85	6	fda	fda	PROPN
dti-1415	85	7	approves	approve	VERB
dti-1415	85	8	label	label	NOUN
dti-1415	85	9	changes	change	NOUN
dti-1415	85	10	for	for	ADP
dti-1415	85	11	asthma	asthma	NOUN
dti-1415	85	12	drug	drug	PROPN
dti-1415	85	13	xolair	xolair	PROPN
dti-1415	85	14	(	(	PUNCT
dti-1415	85	15	omalizumab	omalizumab	NOUN
dti-1415	85	16	)	)	PUNCT
dti-1415	85	17	,	,	PUNCT
dti-1415	85	18	including	include	VERB
dti-1415	85	19	describing	describe	VERB
dti-1415	85	20	slightly	slightly	ADV
dti-1415	85	21	higher	high	ADJ
dti-1415	85	22	risk	risk	NOUN
dti-1415	85	23	of	of	ADP
dti-1415	85	24	heart	heart	NOUN
dti-1415	85	25	and	and	CCONJ
dti-1415	85	26	brain	brain	NOUN
dti-1415	85	27	adverse	adverse	ADJ
dti-1415	85	28	events	event	NOUN
dti-1415	85	29	.	.	PUNCT
dti-1415	86	1	website	website	NOUN
dti-1415	86	2	.	.	PUNCT
dti-1415	87	1	https://www.fda	https://www.fda	PROPN
dti-1415	87	2	.gov	.gov	PROPN
dti-1415	87	3	/	/	SYM
dti-1415	87	4	drugs	drug	NOUN
dti-1415	87	5	/	/	SYM
dti-1415	87	6	drugsafety	drugsafety	NOUN
dti-1415	87	7	/	/	SYM
dti-1415	87	8	ucm414911.htm	ucm414911.htm	PROPN
dti-1415	87	9	.	.	PUNCT
dti-1415	88	1	updated	update	VERB
dti-1415	88	2	september	september	PROPN
dti-1415	88	3	,	,	PUNCT
dti-1415	88	4	2014	2014	NUM
dti-1415	88	5	.	.	PUNCT
dti-1415	89	1	accessed	access	VERB
dti-1415	89	2	january	january	PROPN
dti-1415	89	3	22	22	NUM
dti-1415	89	4	,	,	PUNCT
dti-1415	89	5	2019	2019	NUM
dti-1415	89	6	.	.	PUNCT
dti-1415	90	1	9	9	X
dti-1415	90	2	.	.	X
dti-1415	90	3	iribarren	iribarren	PROPN
dti-1415	90	4	c	c	PROPN
dti-1415	90	5	,	,	PUNCT
dti-1415	90	6	rothman	rothman	PROPN
dti-1415	90	7	kj	kj	PROPN
dti-1415	90	8	,	,	PUNCT
dti-1415	90	9	bradley	bradley	PROPN
dti-1415	90	10	ms	ms	PROPN
dti-1415	90	11	,	,	PUNCT
dti-1415	90	12	carrigan	carrigan	VERB
dti-1415	90	13	g	g	PROPN
dti-1415	90	14	,	,	PUNCT
dti-1415	90	15	eisner	eisner	PROPN
dti-1415	90	16	md	md	PROPN
dti-1415	90	17	,	,	PUNCT
dti-1415	90	18	chen	chen	PROPN
dti-1415	90	19	h.	h.	PROPN
dti-1415	90	20	cardiovascular	cardiovascular	PROPN
dti-1415	90	21	and	and	CCONJ
dti-1415	90	22	cerebrovascular	cerebrovascular	ADJ
dti-1415	90	23	events	event	NOUN
dti-1415	90	24	among	among	ADP
dti-1415	90	25	patients	patient	NOUN
dti-1415	90	26	receiving	receive	VERB
dti-1415	90	27	omalizumab	omalizumab	NOUN
dti-1415	90	28	:	:	PUNCT
dti-1415	90	29	pooled	pool	VERB
dti-1415	90	30	analysis	analysis	NOUN
dti-1415	90	31	of	of	ADP
dti-1415	90	32	patient	patient	ADJ
dti-1415	90	33	-	-	PUNCT
dti-1415	90	34	level	level	NOUN
dti-1415	90	35	data	datum	NOUN
dti-1415	90	36	from	from	ADP
dti-1415	90	37	25	25	NUM
dti-1415	90	38	randomized	randomized	ADJ
dti-1415	90	39	,	,	PUNCT
dti-1415	90	40	double	double	ADJ
dti-1415	90	41	-	-	PUNCT
dti-1415	90	42	blind	blind	ADJ
dti-1415	90	43	,	,	PUNCT
dti-1415	90	44	placebocontrolled	placebocontrolle	VERB
dti-1415	90	45	clinical	clinical	ADJ
dti-1415	90	46	trials	trial	NOUN
dti-1415	90	47	.	.	PUNCT
dti-1415	91	1	j	j	PROPN
dti-1415	91	2	allergy	allergy	PROPN
dti-1415	91	3	clin	clin	PROPN
dti-1415	91	4	immunol	immunol	PROPN
dti-1415	91	5	.	.	PUNCT
dti-1415	92	1	2017;139:1678–1680	2017;139:1678–1680	X
dti-1415	92	2	.	.	PUNCT
dti-1415	93	1	10	10	NUM
dti-1415	93	2	.	.	PUNCT
dti-1415	94	1	peñaloza	peñaloza	NOUN
dti-1415	94	2	-	-	PUNCT
dti-1415	94	3	martínez	martínez	NOUN
dti-1415	94	4	e	e	NOUN
dti-1415	94	5	,	,	PUNCT
dti-1415	94	6	demelo	demelo	NOUN
dti-1415	94	7	-	-	PUNCT
dti-1415	94	8	rodríguez	rodríguez	NOUN
dti-1415	94	9	p	p	NOUN
dti-1415	94	10	,	,	PUNCT
dti-1415	94	11	proietti	proietti	NOUN
dti-1415	94	12	m	m	PROPN
dti-1415	94	13	,	,	PUNCT
dti-1415	94	14	et	et	PROPN
dti-1415	94	15	al	al	PROPN
dti-1415	94	16	.	.	PROPN
dti-1415	94	17	update	update	NOUN
dti-1415	94	18	on	on	ADP
dti-1415	94	19	extended	extended	ADJ
dti-1415	94	20	treatment	treatment	NOUN
dti-1415	94	21	for	for	ADP
dti-1415	94	22	venous	venous	ADJ
dti-1415	94	23	thromboembolism	thromboembolism	NOUN
dti-1415	94	24	.	.	PUNCT
dti-1415	95	1	ann	ann	PROPN
dti-1415	95	2	med	med	PROPN
dti-1415	95	3	.	.	PUNCT
dti-1415	96	1	2018;50:666–674	2018;50:666–674	PROPN
dti-1415	96	2	.	.	PUNCT
dti-1415	97	1	https://orcid.org/0000-0003-1321-6866	https://orcid.org/0000-0003-1321-6866	PROPN
dti-1415	97	2	https://orcid.org/0000-0003-1321-6866	https://orcid.org/0000-0003-1321-6866	PROPN
dti-1415	97	3	https://www.fda.gov/drugs/drugsafety/ucm414911.htm	https://www.fda.gov/drugs/drugsafety/ucm414911.htm	PROPN
dti-1415	97	4	https://www.fda.gov/drugs/drugsafety/ucm414911.htm	https://www.fda.gov/drugs/drugsafety/ucm414911.htm	PROPN